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ABSTRACT
Unaccustomed exercise consisting of eccentric contractions induces muscle damage that is
characterised by muscle weakness, soreness, swelling and increased muscle stiffness. These
symptoms affect daily activities and athletic performance; therefore, interventions to attenuate the
symptoms and enhance recovery from muscle damage are necessary. Pulsed electromagnetic field
therapy (PEMFT) is anecdotally reported to increase muscle blood flow and oxygenation to
enhance tissue healing. One previous study showed that PEMFT was effective for alleviating
muscle soreness and losses in range of motion after exercise. However, studies investigating the
effect of PEMFT on recovery of muscle strength following eccentric exercise are lacking. The
purposes of this study were to investigate the effects of PEMFT treatment on muscle temperature,
blood flow and oxygenation (Study 1), and on the symptoms associated with eccentric exerciseinduced muscle damage (Study 2).
In Study 1, the effects of 30 min PEMFT on muscle temperature, blood flow and oxygenation
were examined using nine healthy men (23.6 ± 3.7 years). A device called e-cell™was used for
PEMFT in this study, which is the size and shape of a computer mouse weighing approximately 140
g, and sham treatment used a visually identical device without pulsed electromagnetic field
production. PEMFT was applied over the bicep brachii of one arm for 30 min, and the other arm
received sham treatment, while each subject was lying supine on a massage table. The device was
marked A or B; thus, both the investigator and subjects were blinded as to which device was active
e-cell™ or sham, and the use of dominant or non-dominant arm for device A or B was randomised
and counterbalanced among subjects. Pre-treatment muscle temperature was measured by a
thermistor needle (22 gauge, 70 mm) inserted to a depth of 20 mm at 10 mm laterally adjacent to a
near infrared spectroscopy (NIRS) probe unit that was attached to the skin at the mid-belly of the
biceps brachii, and the post-treatment measurement was taken at 5 mm proximal to the first site.
iv

The NIRS was used to measure tissue oxygenation index (TOI), a measure of muscle oxygenation,
and total haemoglobin content (tHb), an indirect measure of blood flow, which were recorded
throughout the treatment period. Changes in muscle temperature from before to immediately posttreatment were compared between e-cell™ and sham conditions using a paired t-test, and changes in
TOI and tHb from baseline to 30 min of treatment (0, 10, 20 and 30 min) were compared between
conditions by a two-way repeated measures analysis of variance (ANOVA). Muscle temperature
significantly (p<0.05) increased after e-cell™ treatment only and was 0.55 ± 0.22°C higher
(p=0.033) for the arm that received e-cell™ than sham treatment. No significant changes in TOI and
tHb were evident for either condition.
In Study 2, eight men and eight women (24.8 ± 6.2 years) performed two bouts of 60 maximal
isokinetic (30°⋅s-1) eccentric contractions of the elbow flexors on each arm separated by 4 weeks. In
each eccentric contraction, the elbow joint was forcibly extended from a flexed (90°) to a fully
extended position (0°). At immediately after, and 1-4 days following the exercise, the exercised arm
received 30 min of either e-cell™ or sham treatment described above. The arm dominance and the
order of treatment conditions were randomised and counterbalanced among the subjects, and the
study was conducted in a double-blinded manner. Dependant variables included maximal voluntary
contraction (MVC) strength, range of motion (ROM), upper arm circumference (CIR), muscle
soreness by a visual analogue scale, muscle tenderness measured by pressure pain threshold (PPT)
and plasma CK activity. Changes in these variables for 7 days following the exercise were
compared between e-cell™ and sham treatment conditions, men and women, and the first and
second bouts of exercise by a two-way repeated measures ANOVA. The changes in the variables
from pre- to post-treatment were also analysed by a two-way repeated measures ANOVA. All
variables changed significantly (p<0.05) following eccentric exercise; however, the changes in the
variables over time were not significantly different between men and women. Thus, men and
women were combined for subsequent analyses. For the acute changes in the variables from pre- to
post-treatment, no significant differences in any variables were evident between e-cell™ and sham
v

conditions. A significant (p<0.05) reduction in MVC by 8% was observed for both conditions, but
no significant changes were found for other variables. Regarding the changes in the variables 1-7
days following exercise, the rate of recovery for MVC strength and ROM was significantly
enhanced, and increases in muscle soreness, CIR and plasma CK activity were significantly
attenuated for the e-cell™ compared with sham condition. When comparing the first and second
bouts by ignoring the treatment, MVC strength and ROM recovered significantly faster, and
increases in CIR and muscle soreness were significantly smaller for bout 2 compared with bout 1,
and these effects were similar or greater than those produced by e-cell™. It was concluded that ecell™ treatment enhanced the recovery of muscle damage; however, the magnitude of recovery
following e-cell™ and sham treatment was influenced in the second bout of exercise by the
contralateral repeated bout effect. Furthermore, pre-conditioning the muscle with non-damaging
exercise could be more effective for attenuating symptoms associated with exercise-induced muscle
damage compared to e-cell™ treatment.
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CHAPTER ONE
INTRODUCTION
1.1 Background
Muscle damage occurs when receiving harmful physical, chemical or biological stimulus. In
exercise and sports or daily activities, muscle damage induced by eccentric contractions is most
common. Downhill running (Byrnes et al., 1985) or walking (Balnave & Thompson, 1993) and
bench stepping (Gleeson, Blannin, Walsh, Field, & Pritchard, 1998) are used to experimentally
induce muscle damage in humans. Other frequently used eccentric exercise models include
maximal or sub-maximal eccentric exercise of the knee extensors (Kellis & Baltzopoulos, 1998)
and flexors (Johansson, Lindstrom, Sundelin, & Lindstrom, 1999) as well as the elbow flexors
(Chapman, Newton, Sacco, & Nosaka, 2006). Among them, the elbow flexor model is most often
used in many previous studies (e.g. Chen et al., 2011; Clarkson & Tremblay, 1988; Cleak & Eston,
1992; Jones, Newham, & Clarkson, 1987).
After performing “unaccustomed” eccentric exercise, muscles become weak, sore, swollen
and stiff for several days (Chen, Lin, Chen, Lin, & Nosaka, 2011; Cleak & Eston, 1992; Nosaka &
Clarkson, 1995; Nosaka, Newton, & Sacco, 2002). To quantify these symptoms, maximal voluntary
contraction (MVC) strength, pain scale, limb circumference or muscle thickness, and range of
motion (ROM) are often used. Other markers of muscle damage include muscle proteins (e.g.
creatine kinase: CK, myoglobin) in the blood, and abnormality detected by ultrasound or magnetic
resonance images (Clarkson & Hubal, 2002; Fleckenstein & Shellock, 1992; Nosaka, Muthalib,
Lavender, & Laursen, 2007). It is important to note that these markers do not necessarily correlate
with one another. For example, muscle soreness does not develop immediately following eccentric
exercise of the elbow flexors but at the same time the greatest decreases in muscle strength loss are
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apparent (Nosaka, 2008). Nosaka et al. (2002) reported that the magnitude of muscle soreness did
not correlate with the magnitude of decrease in maximal isometric strength and range of motion,
increases in upper arm circumference and plasma CK activity. Consequently, it appears that there
are several aspects to eccentric exercise-induced muscle damage (EIMD).
The magnitude of muscle damage incurred after eccentric exercise depends on the training
status of an individual, the force and velocity of contractions, number of repetitions and range of
movement (Chapman, et al., 2006; Cheung, Hume, & Maxwell, 2003; Connolly, Sayers, &
McHugh, 2003; Nosaka & Sakamoto, 2001). Nosaka and Clarkson (1996) reported that it took more
than two months for muscle strength to fully return to baseline levels when untrained individuals
performed maximal eccentric exercise of the elbow flexors. In contrast, Newton and colleagues
(2008) demonstrated that resistance trained men had smaller decreases in muscle strength after
exercise compared with men who had little experience in resistance training, and muscle strength
fully recovered by 3 days following 60 maximal eccentric contractions of the elbow flexors.
Previous studies have demonstrated that the magnitude of muscle damage is greater when greater
force is produced (Nosaka & Newton, 2002), a larger number of contractions are performed
(Chapman, et al., 2006), muscle is stretched more (Nosaka & Sakamoto, 2001) and contraction
velocity is faster (Chapman, Newton, Mcguigan, & Nosaka, 2008).
There are also studies that report gender differences exist for the changes in muscle damage
markers. For example, Seawright et al. (2008) compared the muscle damage markers between 58
women and 42 men after 50 maximal eccentric contractions of the elbow flexors, and reported that
women showed greater relative strength losses than men immediately after exercise, but men had
significantly higher peak CK activity than women. In contrast, Rinard and associates (2000)
showed that gender had no significant effect on muscle damage markers following 70 maximal
eccentric contractions of the elbow flexors performed by 83 women and 82 men. Therefore, it
remains unclear as to whether gender affects the magnitude of eccentric exercise-induced muscle
damage.
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Since muscle damage is often inevitable, therapeutic interventions are needed to alleviate the
symptoms of muscle damage and facilitate the recovery process. Several different types of
interventions have been investigated for their efficacy on the symptoms and markers of muscle
damage experimentally induced by various eccentric exercises. Some examples of interventions
include eccentric contractions, cryotherapy (ice massage, ice packs), electrotherapies (ultrasound,
transcutaneous electrical nerve stimulation: TENS, diathermy), physical therapies (stretching,
massage, compression), nutritional supplements and non-steroidal anti-inflammatory drugs among
others (Allen, Mattacola, & Perrin, 1999; Burgess & Lambert, 2010; Cheung, et al., 2003;
Connolly, et al., 2003; Howatson & van Someren, 2008). As explained previously, symptoms
associated with EIMD are dissimilar in that they typically peak on separate days; nevertheless,
therapeutic modalities should primarily focus on attenuate delayed onset muscle soreness (DOMS)
and enhancing the recovery of muscle function after exercise, since these aspects of EIMD can
directly affect daily activities and athletic performance.
The effect of therapeutic interventions in the treatment of EIMD of the elbow flexors has
previously been investigated. Some examples include, deeply applied sport massage (10 minutes
effleurage and petrissage) that was performed at 3 hours post exercise and reported to alleviate
muscle soreness and swelling but had no effect on enhancing the recovery of muscle function after
maximal eccentric exercise of the elbow flexors (Zainuddin, Newton, Sacco, & Nosaka, 2005).
Similarly, Denegar and Perrin (1992) compared 5 treatment groups (8 untrained women per group)
consisting of TENS, ice pack, a combination of TENS and ice pack, sham TENS and control in
which the therapeutic treatment was performed 48 hours after elbow flexor exercise with a
dumbbell. Their study showed that the combination of TENS and ice pack and the ice pack
treatments had a significant analgesic effect, but no significant effect on recovery of muscle
strength. Weber and colleagues (1994) compared therapeutic massage (2 min light effleurage, 5 min
petrissage followed by 1 min effleurage), microcurrent stimulation and upper body ergometry (60
rpm for a workload of 400 kgm/min) applied immediately and 24 hours after exercise, and reported
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that none of the treatments had a significant effect on alleviating muscle soreness and maximal
isometric contraction strength following dumbbell exercise of the elbow flexors until exhaustion.
Considering the above and other studies (e.g. Allen, et al., 1999; Bonacci & Higbie, 1997;
Tourville, Connolly, & Reed, 2006), it appears that most of the interventions tested in the previous
studies were not strongly effective for attenuating DOMS and enhancing muscle function recovery.
Therefore it is necessary to establish an improved therapeutic treatment for EIMD.
Pulsed electromagnetic field therapy (PEMFT) is an electrotherapy that uses an alternating
current through a copper coil to produces a magnetic field that penetrates deeply through tissues and
is believed to enhance cellular repair, reduce pain, oedema and inflammation (Markov, 2007;
Robertson, Ward, Low, & Reed, 2006). There is significant evidence to suggest that PEMFT can
treat non-union fractures, avascular necrosis, and alleviate pain in chronic musculoskeletal injuries
such as osteoarthritis (Trock et al., 1993), carpal tunnel syndrome (Weintraub & Cole, 2008), and
post operative pain following breast augmentation (Hedan & Pilla, 2008). Trock et al. (1993) used
low frequency (less than 30 Hz) PEMFT consisting of 18 treatment sessions (30 minutes / session)
in comparison to sham treatment (applied treatment by not energizing the magnetic coil) to treat
patients with osteoarthritic pain, and reported that the PEMFT treatment group had significant pain
relief from baseline measurements (up to 50% reduction on 10 cm VAS) compared with sham
treatment group (10% reduction). An in vivo study demonstrated that PEMFT treatment augments
angiogenesis, which can assist in the repair of injured tissue (Tepper et al., 2004). The supply of
oxygen and nutrients via the blood vessels is known to be essential for tissue repair (Zampetaki,
Kirton, & Xu, 2008), thus if PEMFT treatment can increase blood flow and muscle oxygenation, a
more rapid recovery of injured tissue could follow. However, experimental studies measuring the
changes in blood flow following PEMFT treatment are lacking.
To the best of our knowledge only one study has investigated the effects of PEMFT on the
signs and symptoms of muscle damage. Spodaryk (2002) had 36 healthy men perform exhaustive
eccentric exercise of the elbow flexors using a dumbbell and then applied either 20 minutes of
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PEMFT or sham treatment for 5 days starting from immediately post-exercise and found significant
attenuation of muscle soreness (VAS) and smaller decreases in ROM in PEMFT treatment group
only but no enhanced recovery of muscle strength.
A portable low frequency PEMFT device called e-cell™ (Global Energy Medicine, Western
Australia, see Appendix A), which has been cleared by the Australian Register of Therapeutic
Goods, is anecdotally reported to increase blood flow and cellular proliferation, reduce
inflammation and enhance the healing of muscle strain injuries, tendonitis and contusions.
Furthermore, swelling that occurs with the movement of inflammatory cells and fluids to an injured
area following strenuous unaccustomed eccentric exercise is known to contribute to the sensation of
pain (Connolly, et al., 2003). As a consequence, if the e-cell™ treatment was to reduce oedema, the
associated DOMS could be eased. As mentioned earlier PEMFT treatment has been shown in vivo
studies to stimulate cellular repair. If e-cell™ treatment is effective for regeneration of skeletal
muscle fibres and connective tissue surrounding the fibres, it is possible that the treatment could
enhance muscle function recovery after eccentric exercise. Therefore, it seems reasonable to assume
that e-cell™ treatment could be effective for alleviating DOMS and enhancing recovery of losses in
muscle function after EIMD. However, no experimental studies have yet examined the effects of ecell™ treatment on markers of muscle damage induced by eccentric exercise.

1.2 Purpose
The purposes of the present study were to investigate whether 30 minutes of e-cell™
treatment would effect muscle temperature, blood flow and oxygenation compared to sham
treatment when it was applied to the elbow flexors (Study 1). To compare changes in the dependent
variables of muscle damage of the elbow flexors seen in e-cell™ and sham treatment arms when
applied 30 minutes, 1, 2, 3 and 4 days after eccentric exercise of the elbow flexors (Study 2).
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1.3 Research Questions
1) Does 30 minutes of e-cell™ treatment increase biceps brachii temperature? (Study 1)
2) Does 30 minutes of e-cell™ treatment increase muscle oxygenation and blood flow in the
biceps brachii? (Study 1)
3) Does e-cell™ treatment improve MVC torque, ROM, upper arm circumference, muscle
soreness and tenderness acutely? (Study 2)
4) Does e-cell™ treatment influence muscle damage markers (MVC torque, ROM, upper arm
circumference, muscle soreness, tenderness and plasma CK activity) following eccentric
exercise of the elbow flexors, and do these differ between genders? (Study 2)
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CHAPTER TWO
LITERATURE REVIEW
Electrotherapy Treatment of Exercise-Induced Muscle Damage
2.1 Introduction
Exercise-induced muscle damage (EIMD) results in symptoms such as prolonged losses of
muscle function, increased passive stiffness, muscle soreness and swelling (Chen, et al., 2011;
Nosaka & Clarkson, 1995; Nosaka, et al., 2002). EIMD is repairable, but could increase the risk of
musculoskeletal injuries, and impair exercise performance and activities of daily living (Cheung, et
al., 2003). Therefore, interventions are needed to attenuate the symptoms of EIMD.
There are many modalities used as interventions for soft tissue injuries. These interventions
can be classified as prophylactic or therapeutic based on the timing of their application. A
prophylactic intervention is characterised by its application prior to an injury. Conversely,
therapeutic interventions are typically applied once the primary damage has already occurred.
However, many of the interventions are used both prophylactically and therapeutically. Some
prevalent prophylactic and/or therapeutic interventions include pre-exercise isometric (Chen, Chen,
Pearce, & Nosaka, 2012) and eccentric contractions (Nosaka, Newton, Sacco, Chapman, &
Lavender, 2005; Nosaka, Newton, & Sacco, 2005), pre- and post-exercise concentric contractions
(Nosaka & Clarkson, 1997; Zainuddin, Sacco, Newton, & Nosaka, 2006), stretching (Chen, et al.,
2011; Pizza, Koh, McGregor, & Brooks, 2002), nutritional supplements (Bryer & Goldfarb, 2006;
Maxwell, Jakeman, Thomason, Leguen, & Thorpe, 1993), non-steroidal anti-inflammatory drugs
(Baldwin, Stevenson, & Dudley, 2001; Hasson et al., 1993), cryotherapy (Howatson & Van
Someren, 2003; Yanagisawa et al., 2003), hot cold contrast baths (Vaile, Gill, & Blazevich, 2007),
massage therapy (Mancinelli et al., 2006; Zainuddin, et al., 2005), compression garments
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(Jakeman, Byrne, & Eston, 2010; Kraemer et al., 2001) and electrotherapies (Bougie, 1997;
Denegar & Perrin, 1992).
Among these, electrotherapies are popular interventions used by medical practitioners for the
treatment of musculoskeletal injuries in conjunction with other therapeutic interventions such as
transcutaneous electrical nerve stimulation (TENS), microcurrent electrical neuromuscular
stimulation (MENS), ultrasound, vibration, pulsed electromagnetic field therapy (PEMFT), light
amplification by stimulated emission of radiation (laser) and diathermy (Brukner & Khan, 2002;
Watson, 2008). An electrotherapy refers to any form of treatment modality that incorporates an
electro-physical component that can be applied externally to the human body to stimulate or
enhance physiological processes to restore normal function (Robertson, et al., 2006; Watson,
2008). Electrotherapies can be categorised into electrical (e.g. TENS and MENS), mechanical (e.g.
ultrasound, vibration), electromagnetic (e.g. PEMFT and laser) and thermal (diathermy) (Brukner
& Khan, 2002; Robertson, et al., 2006).
It has been reported that electrotherapies are effective for enhancing recovery from
musculoskeletal injuries. For example, Trock et al., (1993) applied 30 minutes of PEMFT for 18
sessions to treat patients with osteoarthritic pain, and reported significantly greater pain relief from
baseline measurements in the PEMFT group (up to 50% reduction on 10 cm visual analogue scale)
compared to sham treatment group (10% reduction). Furthermore, it was reported that 56 patients
suffering from chronic leg ulcers received pulsating ultrasound and had a 20% greater healing rate
than traditional bandaging treatment group (Callam, Harper, Dale, Ruckley, & Prescott, 1987).
Similarly, the healing of other musculoskeletal conditions such as non-union bone fractures and
calcific tendonitis were enhanced after electrotherapy treatment (Ebenbichler et al., 1998; Mollon,
da Silva, Busse, Einhorn, & Bhandari, 2008).
Given that electrotherapies can enhance the healing from musculoskeletal injuries, it seems
reasonable to assume that they could also enhance the recovery from EIMD. Several studies have
investigated the effects of electrotherapies on the treatment of symptoms associated with EIMD.
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However, he reported effects vary considerably among the types of electrotherapy employed,
frequency of application, muscle group utilised and their overall effectiveness. This brief literature
review aims to describe some of electrotherapies and potential mechanisms underpinning the
effects of electrotherapies on soft tissue injuries, and to examine the potential efficacy of
electrotherapies in the attenuation of muscle damage symptoms.

2.2 Possible Mechanisms for Electrotherapies to Enhance Recovery from Muscle
Injury
Understanding the physiological changes during electrotherapy treatment is necessary to
validate the efficacy of electrotherapies. To elicit a physiologically favourable response, the target
tissues must absorb the energy emitted from the modalities. For example, dense tissues such as bone
or tendons will elicit favourable responses to higher energy devices compared to lower energy
devices that will benefit less dense tissues such as muscle, nerves and cell membrane activity
(Robertson, et al., 2006). This section provides a brief summation of the theorised physiological
mechanisms affected by electrotherapy modalities (Figure 1).

2.2.1 Mechanical Therapy
2.2.1.1 Ultrasound
Therapeutic ultrasound is a mechanical therapy resulting from the conversion of electrical
energy into soundwaves, employed at frequencies between 0.7 and 3.3MHz, which can penetrate
through the epidermis and be absorbed into the target tissue (Brukner & Khan, 2002; Robertson, et
al., 2006). Clinicians use both continuous (thermal) and pulsed (athermal) ultrasound to treat
various musculoskeletal conditions. Continuous ultrasound involves an uninterrupted stream of
ultrasound waves that are reported to increase muscle blood flow and tissue metabolism (Dyson,
1987). It is traditionally employed during the remodelling phase of wound healing to improve scar
formation (Young & Dyson, 1990). However, during the acute phase of an injury (∼the first 72
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hours post-injurious stimuli), thermal ultrasound is not applied since it will significantly increase
muscle temperature (2 - 4C°) and further exacerbate acute inflammation. Pulsed ultrasound
involves a regularly alternating stream of ultrasound waves thought to stimulate cavitation and
streaming. The soundwaves (frequencies of 0.85 – 3MHz) are believed to penetrate the skin and
generate micron-sized bubbles in the blood or tissue fluids which are then streamed in the direction
of the mechanical force which is thought to influence cell membrane permeability, facilitate tissue
metabolism, diffusion of cellular metabolites and influence the sensation of pain (Brukner & Khan,
2002; Dyson, 1987).

2.2.1.2 Vibration
Vibration therapy is also a mechanical electrotherapy often employed by clinicians at
frequencies between 30 and 50Hz to reduce oedema and alleviate pain from acute and chronic
musculoskeletal injuries (Broadbent et al., 2010; Lundeberg, Nordemar, & Ottoson, 1984;
Yarnitskya, Kunin, Brik, & Sprecher, 1997). When applied to the skin of the target area, it is
believed to modulate the afferent input from sensory units within skeletal muscle, which may
influence the sensation of pain associated with group III and IV afferent nerve fibres (Robertson, et
al., 2006).
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Figure 1: Potential mechanisms leading to the recovery of soft tissue injuries by electrotherapies.
Each electrotherapy has been categorised into groups, where M = mechanical; T = thermal; E =
electrical; EM = electromagnetic. It is then proposed that these electrotherapies may modify
various physiological mechanisms within the body; for example enhanced blood flow or cell
membrane permeability, which can possibly influence factors that affect the rate of muscle
recovery; such as muscle fibre or connective tissue repair. ↓ indicates decrease; ↑ indicates
increase.

2.2.2 Thermal Therapy
2.2.2.1 Diathermy
Diathermy (Shortwave and Microwave) treatment is a thermal electrotherapy that passively
increases muscle temperature via high oscillating electromagnetic frequencies (Brukner & Khan,
2002). Shortwave diathermy for example is typically applied at a frequency of 27.12MHz compared
to the higher frequencies of Microwave diathermy at 434MHz, 915MHz or 2450MHz (Robertson,
et al., 2006). Higher frequency modalities utilising 1MHz or greater are designed to enhance tissue
heating which is believed to influence metabolic processes, enhance muscle blood flow and
11

extensibility in collagen containing tissues (Robertson, et al., 2006). Diathermy is not utilised
immediately post-injury since it will enhance acute inflammation; however, for the treatment of
musculoskeletal injuries, heating tissues is thought to reduce joint stiffness by increasing
extensibility of connective and muscle tissues (Szymanski, 2001), accelerate the removal of oedema
associated with inflammatory processes via enhanced blood and lymph flow and potentially affect
cell membrane permeability (Brukner & Khan, 2002; Collis & Segal, 1988).

2.2.3 Electrical Therapy
2.2.3.1 Transcutaneous Electrical Nerve Stimulation
There is evidence to suggest TENS treatment is effective for pain relief, and in clinical
practice is often the modality of choice for pain control (Johnson, Ashton, & Thompson, 1991).
TENS is an electrical therapy believed to modify sensory stimulation and enhance pain thresholds
facilitating a temporary analgesic response (Robertson, et al., 2006). The frequency, intensity and
duration of TENS modalities can have differing analgesic effects. High frequency, short pulse
duration TENS (80 – 120 Hz; 50 µs) is believed to engage the ‘Pain Gate Control Theory’, which
suggests that stimulating a large area of sensory nerve fibres in the muscle can inhibit afferent
signals sent from a smaller number of sensory nerve fibres and diminish the perception of pain
(Melzack & Wall, 1967). Conversely, low frequency, long pulse duration TENS (2 – 5 Hz; >300
µs) is thought to activate endogenous opioid pathways that aid to inhibit the sensation of pain
(Sluka, Deacon, Stibal, Strissel, & Terpstra, 1999).

2.2.3.2 Microcurrent Electrical Neuromuscular Stimulation
Microcurrent electrical neuromuscular stimulation (MENS) is an electrical therapy similar to
TENS that produces extremely low intensity (100µA - 200µA) and frequency (0.3 – 300Hz) direct
electrical currents believed to attenuate symptoms of musculoskeletal injuries such as pain, swelling
and losses in muscle function (Allen, et al., 1999; Robertson, et al., 2006). Clinically, MENS has
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been used in the treatment of non-union bone fractures (Bertolucci & Grey, 1995) and tissue
healing (Brighton & Friedenberg, 1974). At a cellular level, MENS is believed to influence the
bioelectricity involved with the transport of ions through the cell membrane in order to maintain
membrane permeability, which can facilitate cell proliferation and protein synthesis (Cheng et al.,
1982).

2.2.4 Electromagnetic Therapy
2.2.4.1 Laser
Low-level laser therapy has been advocated as an effective therapeutic treatment for various
musculoskeletal conditions such as the relief of pain (Chow, Heller, & Barnsley, 2006) and
accelerating wound healing (Gur et al., 2002). Clinically, lasers are used at two wavelengths, with
the helium neon (HeNe) laser at 632.8nm and the gallium arsenide (GaAs) laser at 904nm (Brukner
& Khan, 2002; Enwemeka, 2001); however, other wavelengths of 655nm (Junior et al., 2008) and
830nm (Junior et al., 2009) have also been reported. It is proposed that the light energy absorbed by
the target tissues can modulate intracellular processes and reduce pain, oedema, improve
mitochondrial function and vascularisation (Brukner & Khan, 2002).

2.2.4.2 Pulsed Electromagnetic Field
Pulsed electromagnetic field therapy (PEMFT) transmits an alternating current through a
copper coil to produce a magnetic field that penetrates deeply through tissues and is believed to
enhance blood flow and cellular repair, reduce pain, oedema and inflammation (Robertson, et al.,
2006). PEMFT is typically applied to treat non-union fractures (Mooney, 1990; Sharrard, 1990),
avascular necrosis (Aaron, Lennox, Bunce, & Ebert, 1989), and alleviate pain in chronic
musculoskeletal injuries such as osteoarthritis (Trock, et al., 1993), carpal tunnel syndrome
(Weintraub & Cole, 2008), and post operative pain following breast augmentation (Hedan & Pilla,
2008).
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2.3 Electrotherapy Interventions for Exercise-Induced Muscle Damage
Many studies have investigated the effects of various interventions on EIMD, but only a
limited number of studies have examined the effects of electrotherapies on the treatment of
symptoms associated with EIMD. This review introduces the studies in which interventions
categorised as electrotherapy were used for the treatment of EIMD. The interventions include
ultrasound and vibration therapy (both mechanical therapies), TENS and MENS (electrical
therapies), pulsed electromagnetic field therapy, diathermy (thermal therapy) and laser therapy
(electromagnetic therapy).

2.3.1 Mechanical Therapy
2.3.1.1 Ultrasound
Many studies have examined the efficacy of ultrasound as an intervention for the recovery of
EIMD, but there is limited evidence validating its effectiveness. For example, a study by Tiidus et
al., (2002) found that 11 subjects who received 8 minutes of daily-pulsed ultrasound after 50
maximal eccentric contractions of the elbow flexors had no significant attenuation of any indirect
markers of muscle damage. Similar findings have also been reported in other elbow flexor studies
(Aytar et al., 2008; Craig, Bradley, Walsh, Baxter, & Allen, 1999; Stay, Richard, Draper,
Schulthies, & Durrant, 1998). Contrastingly, Hasson et al. (1990) found that a single 20-minute
application of pulsed ultrasound significantly enhanced the recovery of muscle soreness and muscle
strength of the quadriceps one-day post-EIMD. Whilst there is some evidence to suggest that
therapeutic ultrasound can enhance the recovery of EIMD, it appears the large majority of literature
indicates that ultrasound has little or no effect in attenuating the signs and symptoms of muscle
damage.
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2.3.1.2 Vibration
With regards to the attenuation of symptoms associated with EIMD, Lau et al. (2011) found that 30minutes of vibration treatment for 5 consecutive days applied to 15 subjects after performing after
60 maximal eccentric contractions of the elbow flexors was effective at attenuating muscle soreness
and losses in ROM but did not affect the recovery of muscle strength, swelling or plasma CK
activity. Similarly, Bakhtiary and colleagues (2007) found that 1-minute of vibration treatment
applied to the knee flexors and extensors of 25 subjects prior to 30 minutes of downhill walking at
4-km per hour on a 10° incline resulted in smaller increases of muscle soreness and plasma CK
activity but no affect on muscle strength recovery. This was also in accordance with the findings
from Ayles, Graveson-Nielsen and Gibson (2011). It appears that like TENS, vibration treatment
can be effective in the treatment of DOMS but has little effect on other markers of EIMD.

2.3.2 Thermal Therapy
2.3.2.1 Diathermy
In the treatment of EIMD, Diathermy is typically applied prophylactically because its application
immediately post-exercise is contraindicated. Nosaka et al. (2004) found that 10 female subjects
who received 10 minutes of microwave diathermy (27.12MHz, 100W) immediately after
performing 12 maximal eccentric contractions of the elbow flexors had no significant attenuation of
muscle damage symptoms. Conversely, Nosaka and colleagues (2007) reported that 15 males who
received 20 minutes of microwave diathermy treatment (150 W) 18 ± 0.4 hours prior to performing
24 maximal eccentric contractions of the elbow flexors had significant attenuation of muscle
soreness, faster recovery of muscle strength, as well smaller decreases in range of motion compared
to control. Thus, it appears that the muscle temperature, time duration, and time of application prior
to EIMD may influence the effectiveness of diathermy treatment.
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2.3.3 Electrical Therapy
2.3.3.1 Transcutaneous Electrical Nerve Stimulation
A study by Denegar and Perrin (1992) compared 5 treatment groups (8 untrained women per
group) consisting of TENS, ice pack, a combination of TENS and ice pack, sham TENS and control
in which the therapeutic treatment was performed 48 hours after elbow flexor exercise with a
dumbbell. They reported the combination of TENS and ice pack treatment had a significant
analgesic effect, but no significant effect on the recovery of muscle strength and other markers.
Conversely, Craig et al. (1996) found that low and high frequency pulsating TENS applied for 20
minutes to 24 subjects (n=12 per group) after performing 24 maximal eccentric contractions had no
significant effect on the recovery of muscle damage symptoms. Thus, given the aforementioned
studies, TENS may have a small influence on the perception of pain in relation to muscle soreness,
but it appears that TENS has little or no influence on other muscle damage markers. Given that the
recovery of muscle function, most notably muscle strength, is perhaps the most important muscle
damage variable (Warren, Lowe, & Armstrong, 1999), TENS appears limited as an effective
electrotherapy for the treatment of muscle damage.

2.3.3.2 Microcurrent Electrical Neuromuscular Stimulation
Studies investigating the effects of MENS on the symptoms of EIMD appear to have
conflicting results. Curtis and colleagues (2010) found that 20-minutes of MENS treatment
employed at varying frequencies (18 - 191Hz) and an intensities (100 - 200µA) applied after 75
maximal voluntary eccentric contractions of the knee flexors provided significantly less soreness
compared to control. Conversely, Allen et al., (1999) found that 20-minutes of MENS treatment (10
minutes at 30Hz, 200µA and 10 minutes at 0.3Hz, 100µA) had no significant effect on reducing
pain or losses in ROM compared to sham treatment after exhaustive eccentric exercise of the elbow
flexors using a dumbbell. In addition, Weber et al., (1994) compared between MENS, therapeutic
massage and upper body ergometry groups with 8 minutes of the treatments applied immediately
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after and 24 hours after maximal exhaustive eccentric contractions of the elbow flexors, and
reported that none of the interventions had a significant effect on alleviating muscle soreness and
maximal isometric contraction strength.

2.3.4 Electromagnetic Therapy
2.3.4.1 Laser
Studies evaluating the effectiveness of laser therapy on muscle damage symptoms have been
conflicting. Baroni et al., (2010) found that when 18 males (36 total) were exposed to laser therapy
(810 nm, 200mW) for 3 minutes (30 seconds in each of 6 points of the quadriceps) and applied 24 ±
1 hours prior to 75 maximal eccentric contractions of the knee extensors, they had significantly
smaller increases in plasma CK activity and lactate dehydrogenase, smaller decreases and faster
recovery of isometric strength but no change in the recovery of muscle soreness (VAS) compared to
placebo treatment. Conversely, Craig et al., (1999) showed that 4 minutes of combined low
intensity laser therapy/phototherapy (660-950nm, 534mW) applied after 18 males and 18 females
performed 3 sets of maximal exhaustive eccentric contractions of the elbow flexors using a
dumbbell had no significant attenuating effect on any signs of muscle damage compared to placebo
and control conditions. Since the exercise and laser therapy treatment protocols were different in the
aforementioned studies, it is difficult to make a direct comparison between the two. However, it
appears that laser therapy can provide prophylactic effects when applied approximately one day
prior to EIMD of the knee extensors. Given that only one study has demonstrated the efficacy of
laser therapy, further evidence is required to determine whether this therapy is an effective
treatment for EIMD.
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2.3.4.2 Pulsed Electromagnetic Field
To the best of our knowledge, only one study that has investigated the effects of PEMFT
treatment on the signs and symptoms of muscle damage. The study by Spodaryk (2002) had 36
healthy men perform exhaustive eccentric exercise of the elbow flexors using a dumbbell, and were
treated for 20 minutes of PEMFT for 5 days, starting from immediately post-exercise, had
significant attenuation of muscle soreness (VAS) and smaller decreases in ROM. However, they did
not report on the recovery of strength or plasma CK activity. Consequently, it remains unclear as to
whether PEMFT affects the recovery of muscle function following eccentric exercise.

2.4 Conclusion
The limited evidence suggests that the majority of electrotherapies are strongly effective for
attenuating DOMS, enhancing the recovery of muscle function or other symptoms of EIMD. Of the
electrotherapy studies reviewed, several found some effect on reductions in muscle soreness and
swelling, but very few studies have found any significant effect on muscle function recovery. The
recovery of muscle function, particularly the ability to generate force, is regarded as the most
critical marker of muscle damage due to its impact on exercise performance and its requirement to
complete activities of daily living. Given that the recovery of muscle strength is the most important
marker of muscle damage, only one electrotherapy study, employing pulsed ultrasound, has
reported a significant effect on the recovery of muscle strength following EIMD. This suggests that
existing electrotherapies have not been particularly effective in the treatment of EIMD and a more
effective electrotherapy must be established for the treatment of symptoms associated with EIMD.
The electrotherapy PEMFT is believed to influence a number of physiological mechanisms
including enhanced blood flow and cell membrane permeability and may have the greatest potential
to enhance the healing of soft tissue injury and attenuate the symptoms associated with EIMD.
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CHAPTER THREE
METHODS

3.1 STUDY 1 – The effects of 30 minutes of e-cell and sham treatment on muscle
temperature, muscle blood flow and oxygenation of the biceps brachii

3.1.1 Participants
Nine healthy male volunteers (23.6 ± 3.7 years, 176.5 ± 4.5 cm, 74.6 ± 5.9 kg) were recruited
from the staff and students of Edith Cowan University for this study following approval from the
Human Research Ethics Committee. Participants were free from musculoskeletal injuries to the
upper body and none were taking medication or dietary supplementation before participating. All
participants completed an informed written consent form and a medical questionnaire prior to
testing.

3.1.2 Experimental Design
A company (Global Energy Medicine, WA, Australia) provided two identical e-cell™
devices; one being the actual e-cell™ and the other a sham device that did not generate
electromagnetic pulses. The investigator and participants were blinded to the devices (only
informed as Device A and Device B). Participants were required to attend one testing session where
one arm received e-cell™ treatment and the other arm received sham treatment. The treatment
device used and the choice of arm (dominant arm versus non-dominant arm) were chosen at random
and counterbalanced among the participants.
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The dependant variables measured were muscle temperature, blood flow (total haemoglobin
volume) and muscle oxygenation (tissue oxygenation index). Changes in the measures after
treatment were compared between the e-cell™ and sham treatment.

3.1.3 e-cell™ and Sham Treatments
Each subject lay supine on a massage table and requested to keep both arms as still as
possible until the treatment period had concluded to minimise changes in blood flow and muscle
temperature due to movement. The devices (similar in shape and size to a computer mouse,
powered by a rechargeable internal battery and weighing approximately 140 g) were placed
longitudinally along the lateral aspect of the biceps brachii and held in place with adhesive tape,
aligning the midpoint of the device with the mid-belly of the biceps brachii (Figure 2). The e-cell™
and sham treatments were applied for 30 min. When the devices were switched on, green and red
lights would flash to indicate they were operating and then turned off after 30 min of treatment
indicated by the sound of a double beep. A stopwatch was also used to ensure the 30 min treatment
time was adhered to.

Figure 2: e-cell™ and sham treatments applied to the subjects arm.
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3.1.4 Muscle Temperature
Changes in muscle temperature was measured by a thermometer (model N550; Nikkiso- YSI
Co., Ltd, Tokyo Japan), with a needle thermistor probe as shown in figure 3 (model N451; NikkisoYSI Co., Ltd, Tokyo Japan) inserted to a depth of 20mm, corrected for skin thickness, at a 45°
angle into the biceps brachii, and the muscle temperature was recorded after stabilisation. The
thermometer and thermistor was calibrated according to the manufacturers specifications before
testing each subject. The sterilised thermistor probe (22 gauge, 70mm) was then inserted at 4 sites
(2 measurements for each arm). The first site was standardised at 10mm laterally adjacent to the
NIRS probe determined as one-third the distance from the lateral epicondyle of the humerous to the
lateral aspect of the acromion process, and the second site was 5 mm above the first site.
Measurements were taken 5 min before and 30 min (immediately after) after treatment. The
temperature measures were counterbalanced between participants as to whether e-cell or sham arm
was recorded first.

Figure 3: Muscle temperature thermistor probe needle (a) and 2 insertion sites (b).
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3.1.5 Muscle Oxygenation and Blood Flow
Changes in muscle oxygenation and blood flow in the biceps brachii was measured using a NIRO200 (Hamamatsu Photonics, Japan) NIRS system (Figure 4). The NIRO-200 optical probe unit consists
of one emitter (laser emitting diodes of 775, 810 and 850 nm) and one detector (two silicon photodiodes
separated by a 6 mm centre-centre distance) that measures changes in oxygenated-haemoglobin (O2Hb),
deoxygenated-haemoglobin (HHb) and the total haemoglobin volume (tHb = O2Hb + HHb). The tissue
oxygenation index (TOI) can then be expressed as a percentage (TOI = O2Hb / tHb x 100). Thus
changes observed in tHb can be considered as an indirect measure of changes in blood flow and changes
in TOI reflect the percentage of O2 remaining in the bloodstream. The NIRS system was calibrated prior
to each testing session according to the manufacturers standard procedures. The probe unit was firmly
attached to the skin at the mid-belly of the biceps brachii with double-sided adhesive tape to ensure no
sliding of the probe on the skin. The NIRS probe in relation to the treatment device was aligned
adjacently with minimal direct contact between the two (less than 140 g of weight), and the midpoint of
both was aligned with the mid-belly of the biceps brachii. The NIRO-200 system recorded TOI and tHb
levels from 5 min prior to the onset of treatment and continued until the treatment concluded (30 min).
Baseline measures of TOI and tHb were determined as the mean value over 1 min before the onset of
treatment following 4 min of complete rest. TOI and tHb were also continuously recorded using the
PowerLab (Australia) and then averaged for every 10 mins (0, 10, 20 and 30 min) and used for further
analysis.

Figure 4: NIRS probe located on the biceps brachii.
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3.1.6 Statistical Analysis
Changes in muscle temperature from baseline to 30 min (immediately post-treatment) were
analysed using a paired t-test and changes in TOI and tHb from baseline to 30 min (0, 10, 20 and 30
minutes) were compared between the e-cell™ and sham treatments using a two-way repeated
measures analysis of variance (ANOVA) using SPSS for Mac (Version 19, SPSS Corp, Chicago,
Illinois). Data analysis was performed by a statistical significance set at P<0.05.

3.2 STUDY 2 – The effects of e-cell and sham treatment on muscle damage
symptoms

3.2.1 Participants
A total of 16 volunteers, 8 men (26.1 ± 6.1 years; 177.1 ± 7.8 cm; 80.1 ± 13.4 kg)
and 8 women (23.4 ± 4.2 years; 170.1 ± 10.4 cm; 67.1 ± 9.6 kg), were recruited for this study. The
sample size was calculated by the equation “N=2+C(s/d)2” where “N” is the number of participants,
“C” is a constant that depends on values chosen for α and β (when α=0.05, β=0.8, C=7.85), “s” is
the standard deviation of the population means and “d” is the difference to be detected. Based on
the data from a previous study using the same eccentric exercise (Zainuddin, et al., 2006), muscle
soreness measures are expected to be around 50 with a standard deviation of 20 (50 ± 20mm). It is
assumed that 30% reduction in muscle soreness is physiologically significant and the e-cell™
treatment could result in 15mm reduction in muscle soreness over all with a power of 80% and a
significance level of 5%. Therefore, “s” is 20 and “d” is equal to 15 for the equation.
N = 2+C(s/d)2 = 2 + (7.85)(20/15)2 = 15.95
Thus, 16 participants were recruited for this study, which was divided into 8 men and 8
women. All participants completed an informed written consent form and medical questionnaire
prior to the onset of the study. Female participants were also required to complete a menstrual
history questionnaire. Ethical approval from the Human Research Ethics Committee was ensured
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prior to commencing the study. The participants had not performed resistance training of the upper
limbs for at least six months prior to the study. They did not have any current or previous injury of
the elbow joints, elbow flexors, tendons and other tissue around the joints, had no neuromuscular
disorders and were not taking any medications. Participants were requested not to change their
lifestyle and diet, not to take any anti-inflammatory drugs or nutritional supplements and not to
perform unaccustomed exercise during the experimental period.

3.2.2 Experimental Design
This was a double-blinded, randomised, crossover design study. As previously mentioned, the
company provided two identical e-cell™ devices; one being the actual e-cell™ and another that did
not generate electromagnetic pulses (sham). Participants performed a bout of maximal eccentric
exercise of the elbow flexors of each arm 4 weeks apart. Female participants performed the exercise
during the mid-follicular phase (lowest oestrogen and progesterone levels) of their menstrual cycle,
since oestrogen may have a protective effect on skeletal muscle and may therefore reduce the
markers of eccentric exercise-induced muscle damage (Kendall & Eston, 2002). One arm received
e-cell™ treatments and the other arm received sham treatments on five occasions such as 30
minutes after the exercise, and 1, 2, 3 and 4 days following the exercise. The treatment duration was
30 minutes for each occasion, which is normally used in the e-cell™ treatment. The experiment
period included one block of 9 days for the first bout (familiarisation session, reliability testing
session 3 days before exercise, before and immediately after exercise, 1, 2, 3, 4, 5, and 7 days postexercise) and one block of 7 days of testing for the second bout (before and immediately after
exercise, 1, 2, 3, 4, 5, and 7 days post-exercise). In the testing session, maximal voluntary isometric
contraction (MVC) torque of the elbow flexors, range of motion (ROM) of the elbow joint, upper
arm circumference, muscle soreness and pressure pain threshold (PPT) of the elbow flexors, and
blood samples to assess plasma creatine kinase (CK) activity were taken. Changes in these
measures over time were compared between the conditions. To examine the acute effects of the
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treatment, MVC torque, ROM, upper arm circumference, muscle soreness and PPT measurements
were taken immediately after the treatments performed 30 min, and 1, 2, 3 and 4 days post-exercise,
and were also compared between conditions.

3.2.3 Familiarisation Session
Participants participated in a familiarisation session before they participated in the study.
Participants were restricted to performing 2 maximal isometric contractions at 60˚ and 2 maximal
isokinetic concentric contractions at 30˚·s− and 210˚·s− during this session on the lever arm of the
isokinetic dynamometer (Cybex 6000, Lumex Inc. Runkonkoma, USA). No eccentric contractions
were performed to minimise any muscle damage to the elbow flexors. However the participants
were shown and briefed on the eccentric exercise protocol. Measurements including ROM, upper
arm circumference, muscle soreness and PPT, and plasma CK activity were also demonstrated.

3.2.4 Eccentric Exercise
The exercise protocol consisted of 10 sets of 6 maximum voluntary eccentric contractions of
the elbow flexors against the lever arm of the isokinetic dynamometer moving at a constant velocity
of 30˚·s−. This protocol has been shown to induce muscle damage in previous studies (Chapman, et
al., 2006; Chen, Nosaka, & Sacco, 2007; Saka et al., 2009). Participants were randomly chosen to
perform the initial bout of exercise with either their dominant or non-dominant arm and they were
individually positioned on a seated preacher arm curl bench with a supinated forearm position and
the elbow aligned with the axis of rotation of the dynamometer. The elbow joint was forcibly
extended from a flexed position (90˚) to a fully extended position (0˚) in 3 seconds (Figure 5).
Participants were verbally encouraged to generate a maximal isometric force at the starting position
and to maximally resist against the elbow extending action throughout the full range of motion.
After each eccentric action, the isokinetic dynamometer returned the arm to the flexed position at a
constant velocity of 9˚·s− while participants were asked to relax the arm, creating a 10 second
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passive recovery between contractions. The rest period between sets was 3 minutes. Torque and
displacement signals were obtained directly from the dynamometer output and captured using a data
acquisition hardware and software system (Power Lab, Australia). Average peak torque (Nm) was
determined as the mean peak torque for 6 eccentric contractions over 10 sets and work during
exercise (J) was calculated as the average peak work of the 6 repetitions over 10 sets of the
eccentric exercise bout.

Figure 5: Eccentric exercise protocol. Each eccentric contraction commenced at an elbow joint of
90° (a) and finished at 0° (b).
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3.2.5 e-cell™ and sham Treatments
The e-cell™ (Global Energy Medicine, Australia) was applied to a randomly assigned
exercise arm and the other exercised arm received sham treatment (the device was applied without
electromagnetic pulses). The order of the conditions (e-cell™, sham) as well as the arm dominance
was counterbalanced amongst the participants. The device (similar in shape and size to a computer
mouse, is powered by a rechargeable internal battery and weighs approximately 140 g) was placed
longitudinally along the lateral aspect of the biceps brachii and held in place with a specially
designed Velcro strap, aligning the midpoint of the device with the mid-belly of the biceps brachii
(Figure 6). The Velcro strap (containing the device) was secured on the upper arm so that the
position of the device would not alter throughout the entire treatment period, while also ensuring
the strap was not too tight as to induce the enhanced recovery effects of compression. The subject
was seated in a chair during the entire treatment period. The e-cell™ treatment had a pulse duration
of 380 µs, frequency of 75 Hz with the intensity of the electromagnetic pulse set at 10 mT.

Figure 6: e-cell™ and sham treatments applied to a subject and held in place with a specially
designed Velcro strap.
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3.2.6 Maximal Voluntary Isometric Contraction (MVC) Torque
MVC torque was measured on a Cybex isokinetic dynamometer with a HUMAC system
(CSMI Medical Solutions, Massachusetts, USA) that was connected to a power lab system
(Powerlab, ADInstruments, Castle Hill, Australia). The participants were positioned as they were
for the eccentric exercise protocol. As shown in Figure 7, participants performed two 3-s maximal
isometric contractions at elbow joint angles of 90˚, 60˚ and 30˚ (where 0˚ represents a fully
extended elbow joint angle) in this order with 30 seconds rest between contractions at the same
joint angle and 60 seconds rest between contractions at different joint angles. Participants were
asked to generate maximal force as fast as possible when a signal was given. Verbal
encouragements were given during all muscle strength testing. The higher torque of the two
measures was used for further analysis.

Figure 7: Measurements of MVC torque at 90° (a), 60° (b), and 30° (c) on the preacher arm curl
bench and isokinetic dynamometer.
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3.2.7 Range of Motion (ROM)
A plastic goniometer was used to measure ROM of the elbow joint. The ROM was calculated
as the difference between two types of joint angles; extended elbow joint angle (EANG) and flexed
elbow joint angle (FANG) (Figure 8). The EANG was determined when the subject attempted to
fully extend the elbow joint as much as possible in the same setting as that of RANG. The FANG
was determined when the subject attempted to fully flex the elbow joint to touch the shoulder of the
same side with the palm. To measure these, a semi-permanent ink pen was used to create a mark on
the skin to achieve a consistent measurement. The landmarks where the marks were placed included
the lateral epicondyle of the humerous, the acromion process and the mid point of the styloid
process of the ulna and radius. Measurements were taken twice for each type of joint angle and the
mean value of the two measurements was used for ROM by subtracting FANG from EANG.

Figure 8: Measurements of FANG (a) and EANG (b) using a goniometer.
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3.2.8 Upper Arm Circumference (CIR)
A constant tension tape was used to measure the CIR of the exercise limb while the arm was
hanging relaxed by the subject’s side. The measurements were taken from three sites, the mid-belly
of the biceps brachii determined as half way between the lateral aspect of the acromion process and
lateral epicondyle (Deighan, De Ste Croix, Grant, & Armstrong, 2006), and 3 cm above and below
the mid-belly. Each site was marked with a semi-permanent ink marker to obtain consistent
measures. Measurements were taken twice at each site with the mean of the two measurements
being recorded. The mean measurement from the three sites were summated and averaged to
produce a CIR measure used for further analysis.

Figure 9: Measurements of upper arm circumference with constant tension tape.
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3.2.9 Muscle Soreness
The level of muscle soreness was assessed using a 100 mm visual analogue scale (VAS), in
which 0 mm indicated no pain and 100 mm represented extreme pain. The participants were asked
to mark their level of perceived soreness on the VAS while the corresponding joint was extended by
the investigator with the resulting extension soreness measure used for further analysis. Palpation
was also applied using the index and middle fingers slowly in a circular motion 5 times on three
sites of the upper arm including the mid-belly of the biceps brachii, and 3 cm above and below the
mid-belly. One measurement was taken from each site, which was used for further analysis.

Figure 10: The investigator assessed extension soreness (a) and muscle soreness upon palpation of
the upper arm (b) on the preacher arm curl bench.
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3.2.10 Pressure Pain Threshold (PPT)
PPT is a measure that corresponds with muscle tenderness. It was recorded using an
electronic algometer (Somedic AB, Sweden) with a stimulation area of 1.0 cm. The probe head of
the algometer was placed perpendicular to the measurement sites, which included the mid-belly of
the biceps brachii, 3 cm above and below the mid-belly. Force was gradually applied until the
subject reported the first feeling of noticeable pain. The PPT was performed twice with a 30-s
interval between measures. The absolute value (in kPa) corresponding to the amount of force
applied was noted and the mean of the two measures for each site was recorded. The recorded
absolute value (kPa) was then converted into a percentage with pre-exercise values set at 100%.

Figure 11: Measurements of pressure pain threshold using an electronic algometer.
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3.2.11 Plasma CK Activity
Blood samples were collected from the participants by making a small prick on the end of a
finger and 30 µl of blood was loaded onto a CK test strip (Reflotron CK, Inverness Medical,
Cheshire, UK) and measured by a Reflotron (Roche Diagnosis, Germany). If the plasma CK value
exceeded 1500 U/L, the blood sample was diluted with saline solution.

Figure 12: Measurement of plasma CK activity using a Reflotron.
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3.2.12 Statistical Analysis
Data analyses were performed by a statistical software package (SPSS version 19.0) with a
statistical significance set at p<0.05. Intra-class correlation coefficient (ICC) and coefficient of
variation (CV) statistics were used to calculate the test-retest reliability of all the dependent
variables (Table 1). The comparison between male and female participants for the changes in the
dependent variables over time (pre-, immediately post-, 60 minutes, 1-5 and 7 days post) was
performed using a two-way repeated measures ANOVA. To analyse the acute effects, changes in
measures before and after treatment for days 1-4 were compared between arms by a two-way
repeated measures ANOVA. Changes in the dependent variables over time were also compared
between arms by two-way repeated measures ANOVA. If the ANOVA showed a significant
difference between conditions for main or interaction effect, a LSD post hoc test was applied to find
significant differences between pairs of observations. To examine the magnitude of effect between
exercise and treatment, an independent t-test was performed. Data are presented as means ± SEM,
unless otherwise stated.
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CHAPTER FOUR
RESULTS

4.1 STUDY 1
4.1.1 Muscle Temperature
There were no significant differences (t=2.974, df=8, p=0.324) in pre-exercise measures
between e-cell™ (33.64 ± 0.38°C) and sham (33.97 ± 0.20°C) treatment arms. Figure 13 shows the
changes in biceps brachii muscle temperature, which increased (p<0.05) after e-cell™ treatment
only and was 0.55 ± 0.22°C higher (t=2.751, df=8, p=0.033) than after sham treatment.

! Muscle Temperature (°C)

1.0

0.8

*
Figure 13: Changes in Biceps Brachii
muscle temperature after 30 mins of ecell™ and Sham treatment. *Indicates
significant
difference
(p<0.05)
between e-cell™ and sham treatments.
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4.1.2 Total Haemoglobin Concentration (tHb)
The mean changes in tHb during e-cell and sham treatment are shown in Figure 14. No significant
differences (F1,8=0.324, p=0.808) in the changes in tHb over time were evident between e-cell™ and
sham treatments.
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Figure 14: Changes in total
haemoglobin concentration at 10, 20
and 30 mins after e-cell™ and sham
treatment. n.s No significant
difference was seen between
treatment conditions.

30
20
10
0

0

10

20

30

Time (mins)

4.1.3 Tissue Oxygenation Index (TOI)
There were no significant (F1,8=0.148, p=0.710) changes in TOI from baseline to the end of
treatment for both conditions (Figure 15). Similarly no significant differences (F1,8=2.038, p=0.191) in
the mean changes of TOI over time were evident between e-cell™ and sham treatments.
80

E-cell
Sham

n.s

70

TOI (%)

Figure 15: Mean tissue oxygenation
during 30 minutes of e-cell™ and
sham treatments.
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4.2 STUDY 2
4.2.1 Reliability of Measurements
Intraclass correlations (ICC) and coefficient of variation (CV) were used to assess the testretest reliability over the reliability and pre-exercise testing sessions for the dependant variables
(Table 1). Muscle soreness was not determined as all participants recorded scores of zero on the
VAS for extension and palpation soreness. Values of 0.89 – 1.0 for ICC showed substantial
reliability of the measures. Additionally, all CV values were less than 10% indicating good
reliability.

Table 1: Test-retest reliability of dependent variables using intraclass correlation coefficient (ICC)
and coefficient of variation (CV; 95% CI)
Variable

ICC

CV

MVC torque at 30°

0.95

4.2%

MVC torque at 60°

0.96

4.0%

MVC torque 90°

0.98

3.7%

ROM

0.97

0.6%

CIR

0.95

0.5%

PPT

0.89

8.4%

Plasma CK Activity

0.93

8.4%
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4.2.2 Gender Effects
A comparison was made for the changes in muscle damage markers, regardless of treatment
condition, between male (n=8) and female (n=8) participants post-eccentric exercise (Table 2). This
was done to establish whether gender specific differences existed for any of the criterion measures.
No significant gender differences were found for the dependent variables except for upper arm PPT
(average of 3 bicep sites), with male participants recovering to baseline values by day 5 compared
to females that were still 9% below baseline values but had recovered by day 7. Even if there was a
gender effect for PPT, the counterbalanced arm-to-arm experimental design allows us to combine
the data so that a comparison can still be made between e-cell™ and sham conditions, regardless of
gender.

Table 2: Interaction effect between Male and Female groups
Variable

Group

Time

Interaction

F value

p value

F value

p value

F value

p value

Peak Torque (Nm)

0.546

0.472

390.000

<0.000

1.639

0.110

Total Work (Nm)

0.826

0.378

299.662

<0.000

1.748

0.084

MVC 30° (Nm)

0.177

0.680

67.184

<0.000

2.006

0.061

MVC 60° (Nm)

0.594

0.453

115.064

<0.000

2.051

0.055

MVC 90° (Nm)

0.165

0.691

116.473

<0.000

1.892

0.078

ROM (degrees)

3.775

0.071

47.427

<0.000

1.727

0.099

CIR (mm)

3.583

0.065

14.817

<0.000

1.295

0.253

SOR-Pal (mm)

3.413

0.071

81.282

<0.000

1.605

0.122

SOR-Ext (mm)

0.011

0.918

16.476

<0.000

0.490

0.861

PPT (kPa)

8.615

0.005

91.940

<0.000

5.670

<0.000

CK activity (U/L)

0.010

0.920

11.772

<0.000

0.386

0.886

Note: No significant interaction effect exists between Male and Female participants
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4.2.3 Baseline Values comparing between e-cell™ and sham Conditions
There were no significant differences (p>0.05) for any of the pre-exercise values between ecell™ and sham treatment groups (Table 3) for MVC torque, ROM, CIR, palpation (average of 3
sites) and extension soreness, PPT (average of 3 sites) and plasma CK activity.

Table 3: Absolute baseline values for e-cell™ and sham treatment groups
Variable

E-cell

Sham

F value

df

p value

MVC torque at 30° (Nm)

33.8 ± 3.9

35.3 ± 4.7

1.524

1,15

0.236

MVC torque at 60° (Nm)

43.5 ± 6.7

44.3 ± 8.5

0.474

1,15

0.502

MVC torque 90° (Nm)

51.4 ± 4.5

53.6 ± 5.2

2.478

1,15

0.136

ROM (degrees)

136.1 ± 2.2

136.9 ± 2.9

0.218

1,15

0.668

CIR (mm)

282.3 ± 6.4

283.6 ± 2.5

0.521

1,15

0.459

Palpation Soreness (mm)

0.1 ± 0.1

0.1 ± 0.1

0.000

1,15

1.000

Extension Soreness (mm)

0.1 ± 0.1

0.1 ± 0.1

0.000

1,15

1.000

PPT (kPa)

376.4 ± 12.6

384.1 ± 16.7

0.325

1,15

0.612

Plasma CK Activity (U/L)

121.5 ± 47.6

131.7 ± 66.0

0.243

1,15

0.629

Note: No significant baseline differences between e-cell™ and sham treatments
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4.2.4 Peak Torque during Exercise
There were no significant differences (F1,15=0.093, p=0.765) for the changes in mean peak
torque (mean of 6 contractions for each set over 10 sets) during the eccentric exercise between ecell™ and sham treatment arms (Figure 16). The average peak torque decreased significantly by
approximately 40% over the 10 sets for both treatment conditions.

Average Peak Torque (N!m)
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n.s

Figure 16: Changes in average peak
torque for 6 contractions over 10 sets
for e-cell™ and sham treatment
conditions. N.s: No significant
difference was seen between the arms.
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4.2.5 Work During Exercise
There were no significant differences (F1,15=0.543, p=0.473) in the total work completed for
each of the ten sets of eccentric exercise between arms for both e-cell™ and sham treatment
conditions (Figure 17). Total work completed for the first set was approximately 540 J, which then
decreased significantly by almost 44% from the first to the final set. The total work over the 10 sets
was 3875 ± 79.8 J and 3799 ± 75.4 J for the e-cell™ and sham treatment conditions respectively.

Work During Exercise (J)
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Figure 17: Changes in total work for
6 eccentric contractions over 10 sets
for e-cell™ and sham treatment
conditions. N.s: No significant
difference was seen between the arms.
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4.2.6 Acute Effects of e-cell™ and sham treatments
Changes in criterion measures after exercise were compared between the e-cell™ and sham
treatment to evaluate the efficacy of e-cell™ treatment. There were no significant differences
between conditions for any of the pre-exercise criterion measures however all criterion variables
changed significantly (p<0.05) following the eccentric exercise. There was no significant acute
effect (p<0.05) for the time course changes (days 1 – 4) between e-cell™ and sham conditions for
any of the dependent variables (Figures 18 – 22).

4.2.6.1 MVC torque
No significant differences (F1,15=0.059-1.692, p=0.213-0.811) were found for the changes in
MVC torque between e-cell™ and sham treatments for days 1 to 4, and for any of the elbow joint
angles. However, MVC torque decreased significantly (p<0.05) after the 30 minutes of treatment
for both conditions (Figure 18). The average magnitude of decrease in strength among participants

Maximal Isometric Strength (N!m)

from pre- to post-treatment was 7.5 ± 1.0% for e-cell™ and 7.9 ± 1.3% for sham conditions.
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Figure 18: Changes in MVC torque at 60° before (Pre) and immediately after (Post) treatments for
days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions. * Indicates
significant difference (p<0.05) between Pre and Post.
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4.2.6.2 ROM
There were no significant changes (F1,15=0.546, p=0.471) in ROM measures from pre- to
post-treatment for days 1 to 4 for both treatment conditions (Figure 19).
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Figure 19: Changes in range of motion from before (Pre) and immediately after (Post) treatment
for days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions.

4.2.6.3 CIR
No significant changes (F1,15=1.911, p=0.144) in CIR were evident from pre- to post-

Upper Arm Circumference (mm)

treatment for days 1 to 4 for both e-cell™ and sham treatments (Figure 20).
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Figure 20: Changes in CIR (average of 3 sites including the mid-belly of the biceps brachii, and 3
cm above and below the mid-belly) from before (Pre) and immediately after (Post) treatment for
days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions.
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4.2.6.4 Muscle Soreness
Muscle soreness with palpation (F1,15=0.647, p=0.434) and extension (F1,15=0.148, p=0.706)
was not changed from pre- to post-treatment for days 1 to 4 for e-cell™ and sham conditions. Figure
21 represents the muscle soreness measures during palpation, which was similar for extension

Palpation Muscle Soreness (mm)

muscle soreness.
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Figure 21: Changes in palpation muscle soreness (average of 3 sites including the mid-belly of the
biceps brachii, and 3 cm above and below the mid-belly) from before (Pre) and immediately after
(Post) treatment for days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions.
4.2.6.5 PPT
Upper arm PPT (F1,15=1.431, p=0.247) did not show any significant changes from pre- to
post-treatment for days 1 to 4 for either e-cell™ and sham conditions. Figure 22 represents PPT of

Pressure Pain Threshold (% of change)

the upper arm (average of 3 biceps sites).
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Figure 22: Changes in acute upper arm PPT (average of 3 sites including the mid-belly of the
biceps brachii, and 3 cm above and below the mid-belly) from before (Pre) and immediately after
(Post) treatment for days 1 – 4 after eccentric exercise for e-cell™ and sham treatment conditions.
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4.2.7 Effect of Treatments on Recovery after Eccentric Exercise
Changes in the criterion measures post exercise were compared between e-cell™ and sham
treatments to examine the therapeutic effect of the treatment.

4.2.7.1 MVC torque
Figure 23 shows the changes in MVC torque at 60°, and the changes at other angles were similar
to that shown. MVC torque decreased significantly (p<0.05) immediately post-exercise by
approximately 55% from baseline but there was no significant difference (F1,15=0.731, p=0.406)
between conditions. However, there was a significant (F1,15=8.903, p=0.009) interaction effect between
conditions, such that following e-cell™ treatment MVC torque had recovered to 91% of baseline
measures compared to only 81% for sham condition after 7 days. This recovery was similar for elbow
joint angles 30° (97% cf. 82%) and 90° (90% cf. 81%) for e-cell™ and sham treatments respectively.
Following post-hoc tests, significant differences were found at days 2, 5 and 7 between conditions. This
was similar for other elbow joint angles that reported significant differences between conditions on days
5 and 7.
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Figure 23: Changes in MVC-60°
torque at baseline (Pre), immediately
post (0), 60 minutes post (60’) and 1
– 5 and 7 days after eccentric
exercise between e-cell™ and sham
treatment conditions. * Indicates a
significant
difference
between
treatment conditions (p<0.05).

4.2.7.2 ROM
Figure 24 shows the changes in ROM over 7 days. Immediately post-exercise, ROM
decreased significantly (p<0.05) by 16% from baseline and there were no significant differences
(F1,15=0.147, p=0.707) between conditions. However, a significant (F1,15=2.546, p=0.013)
interaction effect was found between conditions, with a faster rate of ROM recovery seen in the ecell™ (97%) compared with sham (94%) treatment after 7 days. Post-hoc tests revealed a significant
difference on day 1 between conditions.
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4.2.7.3 CIR
Figure 25 shows the changes in CIR (average of 3 sites) from baseline, which was similar for
each of the three sites that were combined for the CIR measures. CIR increased significantly
(p<0.05) immediately post-exercise for both conditions compared to baseline but there was no
significant difference (F1,15=0.057, p=0.871) between conditions. However, there was a significant
difference (F1,15=10.225, p<0.000) between conditions over 7 days, such that following sham
treatment, CIR increased (p<0.05) from immediately post-exercise compared to e-cell™ treatment
where there was no increase in CIR from immediately post-exercise to day 7. CIR peaked on day 5
for both conditions with 54.1 ± 8.4% less swelling after e-cell™ (5.0 ± 0.8mm) compared to sham
treatment (10.9 ± 1.3mm). Significant differences in CIR were seen at 60 minutes, 2 – 5 and 7 days
post exercise between conditions following post-hoc tests.
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Figure 25: Changes in CIR at baseline
(Pre), immediately post (0), 60 minutes
post (60’) and 1 – 5 and 7 days after
eccentric exercise for e-cell™ and sham
treatment conditions. * Indicates a
significant difference between treatment
conditions (p<0.05).
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4.2.7.4 Muscle Soreness
Figure 26 shows the changes in palpation muscle soreness based on VAS upon palpation for
the arm. Muscle soreness developed from 1-day post-exercise for both conditions; however, there
was significantly (F1,15 =6.158, p=0.010) less palpation soreness of the upper arm (average of 3
bicep sites) after e-cell™ compared to sham treatment over 7 days. For example, when soreness
peaked on day 2 there was a 19% reduction in soreness for e-cell™ (16.8 ± 2.1mm) compared to
sham (20.6 ± 2.0mm) condition. Significant differences were observed 2, 4 and 7 days post-exercise
between conditions following post-hoc tests. There was no significant difference for extension (F1,15
=2.145, p=0.165) muscle soreness between conditions.
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Figure 26: Changes in palpation muscle
soreness (average of 3 sites including the
mid-belly of the biceps brachii, and 3 cm
above and below the mid-belly) at
baseline (Pre), immediately post (0), 60
minutes post (60’) and 1 – 5 and 7 days
after eccentric exercise for e-cell™ and
sham treatment conditions. * Indicates a
significant difference between treatment
conditions (p<0.05).

4.2.7.5 Peak Muscle Soreness
Peak muscle soreness (Figure 27) post-exercise upon palpation of the upper arm (the average
of the 3 bicep sites) occurred between days 1 and 3 and was 14% (t= 2.751, df=15, p=0.041) lower
after e-cell™ (21.1 ± 2.2mm) treatment compared with sham (24.5 ± 2.1mm) treatment.
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Figure 27: Peak muscle soreness
upon palpation of the upper arm
(average of 3 sites including the midbelly of the biceps brachii, and 3 cm
above and below the mid-belly) after
eccentric exercise between e-cell™
and sham treatment conditions. *
Indicates a significant difference
between
treatment
conditions
(p<0.05).
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4.2.7.6 PPT
Muscle tenderness developed (p<0.05) at 1 day post-exercise for both conditions but there
was no difference between treatments. However, there was a significant difference (F1,15=9.754,
p<0.000) in upper arm PPT (average of 3 bicep sites) between e-cell™ and sham treatments (Figure
28), with the e-cell™ treatment arm recovering to baseline values by 5 days compared to sham
treatment which was still 10% below baseline values (p<0.05). Post hoc tests showed significant
differences at 2 – 5 days and 7 days post-exercise between conditions.
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Figure 28: Normalised changes in
PPT of the upper arm (average of 3
sites including the mid-belly of the
biceps brachii, and 3 cm above and
below the mid-belly) at baseline
(Pre), immediately post (0), 60
minutes post (60’) and 1 – 5 and 7
days after eccentric exercise between
e-cell™
and
sham
treatment
conditions. * Indicates a significant
difference
between
treatment
conditions (p<0.05).

4.2.7.7 Plasma CK Activity
Plasma CK activity was significantly higher after day 3 in both conditions; however, there
was significantly lower (F1,15=4.080, p=0.010) increases in plasma CK activity for e-cell™
compared to sham treatment over 7 days (Figure 29). For example when plasma CK activity peaked
on day 5, there was a 49% reduction after e-cell™ (1316.9 ± 536.5mm) compared to sham treatment
(2576.2 ± 681.5mm). Based on post-hoc tests, there were significant differences on days 5 and 7
post-exercise between conditions.
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Figure 29: Changes in plasma CK
activity
at
baseline
(Pre),
immediately Post (0), 60 minutes
post (60’) and 1 – 5 and 7 days
after eccentric exercise between ecell™
and
sham
treatment
conditions. * Indicates a significant
difference
between
treatment
conditions (p<0.05).

7d

4.2.7.8 Peak Plasma CK Activity
Peak plasma CK activity (Figure 30) post-exercise occurred between days 4 and 5 and was
43% (t=3.852, df=15, p=0.035) lower after e-cell™ (1504 ± 542IU/L) treatment compared with
sham (2629 ± 742IU/L) treatment.
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4.2.8 Effects of a Contralateral Repeated Bout of Eccentric Exercise
A comparison was made for the changes in muscle damage markers, regardless of gender or
treatment condition, between the first and second bouts of eccentric exercise when the second bout
was performed on the contralateral arm 4 weeks apart.

4.2.8.1 Pre Exercise Values between the First and Second Bouts of Eccentric Exercise
There were no significant differences in the pre exercise absolute values for any of the
criterion measures between the first and second bouts of eccentric exercise (Table 4).
Table 4: Absolute baseline values for bout 1 and bout 2 groups
Variable

Bout 1

Bout 2

F value

df

p value

MVC torque at 30° (Nm)

35.2 ± 4.6

33.0 ± 4.0

2.761

1,15

0.117

MVC torque at 60° (Nm)

44.9 ± 4.5

43.1 ± 4.4

2.729

1,15

0.119

MVC torque at 90° (Nm)

53.0 ± 4.9

51.4 ± 4.5

2.317

1,15

0.149

Range of Motion (degree)

136.6 ± 2.2

136.3 ± 2.1

0.027

1,15

0.877

Upper Arm Circumference (mm)

283.1 ± 6.1

283.5 ± 2.5

0.078

1,15

0.789

Palpation Soreness (mm)

0.1 ± 0.1

0.1 ± 0.1

0.000

1,15

1.000

Extension Soreness (mm)

0.1 ± 0.1

0.1 ± 0.1

0.000

1,15

1.000

Pressure Pain Threshold (kPa)

378.5 ± 12.2 386.8 ± 14.7

0.010

1,15

0.921

Plasma CK Activity (IU/L)

119.2 ± 11.8 134.0 ± 16.4

0.517

1,15

0.483

Note: No significant baseline differences exist between first and second bouts of eccentric
exercise (p>0.05)
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4.2.8.2 MVC torque
Figure 31 shows the changes in MVC torque at 60°, and the changes at other angles were
similar. MVC torque decreased significantly (p<0.05) immediately post-exercise by approximately
55% from baseline but there was no significant difference (F1,15=0.297, p=0.594) between bouts.
However, recovery of MVC torque was significantly different (F1,15=16.159, p<0.000) between first
and second bouts such that 7 days following the second bout, MVC torque had recovered to 94% of
baseline but the recovery was only 79% for the first bout. This was a similar case for elbow joint
angles at 30° (98% and 80%) and 90° (91% and 80%) between second and first bouts respectively.
Following post-hoc tests, significant differences were found on days 2 – 5 and 7 days post-exercise
between bouts. Interestingly, the magnitude of difference for the recovery of MVC torque between
first and second bouts after 7 days was 5% greater than the magnitude of difference between ecell™ and sham treatment.
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Figure 31: Comparison between the first
(Bout 1) and second (Bout 2) bouts for
the changes in MVC-60° torque at
baseline (Pre), immediately post (0), 60
minutes post (60’) and 1 – 5 and 7 days
after eccentric exercise. * Indicates a
significant difference between bouts
(p<0.05).

4.2.8.3 ROM
Figure 32 shows the changes in ROM over 7 days. Immediately post-exercise ROM decreased
significantly (p<0.05) by 16% from baseline but there was no significant difference (F1,15=1.433
p=0.250) in ROM measures between bouts. There was significantly (F1,15=5.144, p<0.000) faster
recovery of ROM seen in the second bout (97%) compared to the first bout (93%) after 7 days.
Post-hoc tests revealed significant differences on days 1 – 5 between bouts. Similarly, the
magnitude of difference in the recovery of ROM between first and second bouts was only 1%
greater than the magnitude of difference between and e-cell™ and sham treatment.
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4.2.8.4 CIR
Figure 33 shows the changes in CIR (average of 3 sites), which was similar for all circumference
measures. CIR increased (p<0.05) immediately post-exercise for both bouts compared to baseline; but
there was no significant difference (F1,15=0.066, p=0.799) between bouts. However, there was a
significant difference (F1,15=15.201, p<0.000) between bouts over 7 days, such that following the first
bout of exercise, CIR increased (p<0.05) from day 1 post-exercise compared to the second bout of
exercise where there was no significant increase in CIR from immediately post-exercise to day 7. CIR
peaked on day 5 for both bouts with 60% less swelling after the second bout (4.6 ± 0.7mm) compared to
the first bout (11.3 ± 1.2mm). Significant differences in CIR were seen at 60 minutes, 1 – 5 days and 7
days post-exercise between bouts following post-hoc tests. Interestingly, the magnitude of difference in
CIR on day 5 post-exercise between the first and second bouts was 6% greater than the magnitude of
difference on day 5 between e-cell™ and sham treatment.
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Figure 33: Comparison between the
first (Bout 1) and second (Bout 2)
bouts for the changes in CIR at
baseline (Pre), immediately post (0),
60 minutes post (60’) and 1 – 5 and 7
days after eccentric exercise. *
Indicates a significant difference
between bouts (p<0.05).
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4.2.8.5 Muscle Soreness
Figure 34 shows the changes in palpation muscle soreness based on VAS upon palpation for
the arm. Muscle soreness developed from day 1 post-exercise for both bouts; however, there was
significantly (F1,15=9.108, p<0.000) less palpation soreness of the upper arm (average of 3 bicep
sites) after the second bout compared to the first. For example when soreness peaked on day 2, there
was a 26% reduction in soreness after the second bout (15.9 ± 1.9mm) compared to the first bout
(21.4 ± 2.1mm). Significant differences were found 2 – 5 days post-exercise following post-hoc
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tests. Comparatively, the magnitude of difference for soreness of the upper arm on day 2 between
the first and second bouts of exercise was 7% greater than the magnitude of difference between ecell™ and sham treatment. A significant difference (F1,15=4.433, p<0.000) was also found for
extension muscle soreness between bouts.
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Figure 34: Comparison between the
first (Bout 1) and second (Bout 2) bouts
for the changes in palpation muscle
soreness (average of 3 sites including
the mid-belly of the biceps brachii, and
3 cm above and below the mid-belly) at
baseline (Pre), immediately post (0), 60
minutes post (60’) and 1 – 5 and 7 days
after eccentric exercise. * Indicates a
significant difference between bouts
(p<0.05).
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4.2.8.6 Peak Muscle Soreness
Peak muscle soreness (Figure 35) post-exercise upon palpation of the upper arm (the average
of the 3 bicep sites) occurred between days 1 and 3 and was 33% lower (F1,15=5.348, p<0.000) after
the second bout (18.3 ± 2.0mm) compared with the first (27.2 ± 2.2mm). Additionally, the
magnitude of difference for peak soreness upon palpation between the first and second bouts was
19% greater than the magnitude of difference between e-cell™ and sham treatment.
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and below the mid-belly) after eccentric
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4.2.8.7 PPT
Muscle tenderness developed (p<0.05) at 1 day post-exercise for both conditions and there
was a significant difference (F1,15=11.023 p<0.000) between bouts. Additionally, there was a
significant difference (F1,15=16.891, p<0.000) in upper arm PPT (average of 3 bicep sites) between
bouts (Figure 36), with the second bout recovering to baseline values by day 5 compared to sham
treatment that was still 13% below baseline values and still had not recovered by day 7. Post hoc
tests revealed significant differences at 60 minutes, 1 – 5 and 7 days post-exercise between bouts.
Similarly, the magnitude of difference for the recovery of muscle tenderness between the first and
second bouts was 3% greater than the magnitude of difference between e-cell™ and sham treatment.
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Figure 36: Comparison between the
first (Bout 1) and second (Bout 2)
bouts for the normalised changes in
PPT of the upper arm (average of 3
sites including the mid-belly of the
biceps brachii, and 3 cm above and
below the mid-belly) at baseline
(Pre), immediately post (0), 60
minutes post (60’) and 1 – 5 and 7
days after eccentric exercise. *
Indicates a significant difference
between bouts (p<0.05).

4.2.8.8 Plasma CK Activity
Plasma CK activity was significantly higher after day 2 for the first bout and day 3 for the
second bout. In addition there was significantly (F1,15=8.995, p=0.009) lower increases in plasma
CK activity for the second bout compared to the first (Figure 37). For example when plasma CK
activity peaked on day 5, there was a 56% reduction after the second bout (1123.5 ± 416.2mm)
compared to the first bout (2547.5 ± 725.8mm). Based on post-hoc tests, there were significant
differences on days 3 – 5 and 7 days post-exercise between conditions. Comparatively, the
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magnitude of difference on day 5 for plasma CK activity between the first and second bouts was 7%
greater than the magnitude of difference between e-cell™ and sham treatment.
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changes in plasma CK activity at baseline
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(60’) and 1 – 5 and 7 days after eccentric
exercise. * Indicates a significant difference
between bouts (p<0.05).
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4.2.8.9 Peak Plasma CK Activity
Peak plasma CK activity (Figure 38) post exercise occurred between days 4 and 5 and was
50% lower (t=6.405, df=15, p=0.010) after the second bout (1386.2 ± 470.3IU/L) compared to the
first bout (2748.3 ± 777.1IU/L). Additionally, the magnitude of difference for peak plasma CK
activity between the first and second bouts was 7% greater than the magnitude of difference
between e-cell and sham treatment.
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4.2.8 Comparison between the Effect of Treatment and Repeated Bout Effect
Our previous analysis showed that both e-cell™ treatment and the contralateral repeated bout
effect enhanced the rate of recovery from muscle damage compared to sham treatment and the first bout
of eccentric exercise respectively. Therefore, a comparison was made to examine whether e-cell™
treatment or the contralateral repeated bout effect was more effective at enhancing recovery from
EIMD. To examine the magnitude of effect between e-cell™ treatment and the contralateral repeated
bout effect, normalised changes in MVC torque, ROM and PPT from baseline (pre: 100%) and absolute
changes in CIR, SOR and plasma CK activity were used. In Figure 39, peak SOR and plasma CK
activity as well as day 5 measures for MVC torque, ROM, CIR and PPT were used to calculate the
magnitude of difference between conditions and exercise bouts for the dependent variables. Compared
with the magnitude of change after the treatment, the second bout of exercise resulted in significantly
faster recovery of MVC torque (p=0.030) and ROM (p=0.041), and smaller increases in SOR (p<0.000)
and PPT (p=0.047). However, no significant difference was seen for CIR (p=0.107) and plasma CK
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Figure 39: Comparison of the magnitude of recovery between the first and second eccentric
exercise bouts and e-cell™ and sham treatment conditions for MVC torque, range of motion, upper
arm circumference and pressure pain threshold on day 5 after eccentric exercise, peak soreness
and CK activity after eccentric exercise. RBE = contralateral repeated bout effect. * Indicates a
significant difference between treatment and exercise (p<0.05).
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4.2.9 Comparison between the First and Second Bouts of Eccentric Exercise for the e-cell™
Treatment Effect
To examine the magnitude of effect between e-cell™ and sham treatments after the first and
second bouts of exercise, normalised changes in MVC torque, ROM and PPT from baseline (pre:
100%) and absolute changes in CIR, SOR and plasma CK activity were used. In Figure 40, peak
SOR and plasma CK activity as well as day 5 measures for MVC torque, ROM, CIR and PPT were
used to calculate the magnitude of effect between conditions for the dependent variables.
Comparatively, the e-cell™ treatment was less effective after the second bout of exercise for the
recovery of MVC torque (12%), ROM (5%), CIR (25%), SOR (14%), PPT (6%) and plasma CK
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activity (29%) compared to the first bout because of the contralateral repeated bout effect.
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Figure 40: Comparison of the mean magnitude of recovery between e-cell™ and sham treatment in
the first and second eccentric exercise bouts for peak SOR and CK activity; and MVC torque, ROM,
CIR and PPT on day 5 after eccentric exercise.
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CHAPTER FIVE
DISCUSSION

The purposes of this thesis were to investigate: the influence of 30 minutes e-cell™ treatment
on muscle temperature, blood flow and oxygenation when it was applied to the elbow flexors
compared to sham treatment (Study 1); the acute, overall, and gender effects of 30 minutes e-cell™
treatment, applied over 5 consecutive days after eccentric exercise of the elbow flexors, on the
associated symptoms and markers of eccentric exercise-induced muscle damage in comparison to
sham treatment (Study 2).
In relation to the research questions, the Study 1 results showed that: 1) e-cell™ treatment
increased muscle temperature by ∼0.5°C compared to sham treatment; 2) however, no significant
differences in muscle blood flow and oxygenation were evident between conditions. In addition,
Study 2 results included: 3) no significant acute changes in the dependent variables from pre- to
post-treatment for either e-cell™ and sham conditions except for an ∼8% decrease in MVC torque
after both conditions; 4) no significant differences between genders for any of the dependent
variables except for a significantly faster recovery of PPT scores for men than women; and when
compared with the sham treatment, the recovery of MVC torque and ROM was significantly faster,
with swelling, peak muscle soreness and peak plasma CK activity also significantly smaller for ecell™ condition. Interestingly, after further analysis, when comparing the first and second bouts
regardless of the treatment condition, the changes in all dependent variables were significantly
attenuated after the second bout than the first bout, and the difference in the magnitude between
bouts was greater than the differences between the treatment conditions. This chapter will discuss
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the main results shown above separately, the potential action of the device, and integrate the
findings to conclude the project.

5.1 Study 1
To the best of my knowledge, no previous studies have investigated the effects of low
frequency PEMFT on muscle temperature, muscle blood flow or oxygenation of the elbow flexors.
Any heat produced in the target muscle after low frequency (5 – 100Hz) PEMFT was thought to
dissipate through the circulating blood (Adey, 1993). However, the present study found that e-cell™
treatment increased muscle temperature by ∼0.5°C (∼1.5% increase), but sham treatment did not.
Given that the devices were applied at the same time and under the same conditions, it is reasonable
to assume that the temperature increase was caused by the e-cell™ treatment. Despite this, the
magnitude of muscle temperature increase observed in the present study was much less than that
reported in studies using higher frequency (27.12 - 2450MHz) devices such as diathermy
(shortwave and microwave) treatment. For example, microwave diathermy studies have reported a
∼3°C muscle temperature increase of the biceps brachii after 10 minutes of treatment (Nosaka, et
al., 2004) and a ∼7°C increase following 20 minutes of treatment (Nosaka, et al., 2007). It is unclear
how the PEMFT treatment increased muscle temperature but some speculation is possible. Higher
frequency electromagnetic devices (>1MHz) are known to generate electromagnetic fields that
stimulate a flow of current in tissues, accelerating the charged ions, which collide with adjacent
molecules producing energy and increasing collisions which leads to heating (Robertson et al.,
2006). Thus, it is possible that the lower frequency device used in the present study was able to
replicate similar heating effects but to a lesser extent.
The physiological importance of the temperature increase in the present study is questionable
given thermal therapies, believed to promote healing, require much greater increases in muscle
temperature to enhance blood flow (Giombini, Di Cesare, Safran, Ciatti, & Maffulli, 2006).
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Therefore, despite the temperature increase after 30-minutes of e-cell™ treatment, there is no
evidence to suggest that such a small passively induced muscle temperature increase is
physiologically meaningful.
Advocates of PEMFT treatment suggest that it can effectively treat soft tissue injuries by
increasing muscle blood flow (Markov, 2007), believing that increased blood flow can promote the
healing of damaged tissues like those affected by muscle damage. However, there are no
documented reports of increased muscle blood flow to passive muscle when low frequency PEMFT
treatment is applied. The mechanism by which PEMFT is believed to influence blood flow is
relatively unknown but it is speculated that nitric oxide maybe the molecule responsible for
vasodilation following PEMFT exposure (Kavaliers, Choleris, Prato & Ossenkopp, 1998). In the
present study near infrared spectroscopy (NIRS) was employed to determine changes in muscle
oxygenation and blood flow. It was found that 30-minutes of e-cell™ treatment had no effect on
muscle blood flow or oxygenation compared to sham treatment. However, it should be noted that ecell™ treatment was applied to healthy individuals with the target tissue (biceps brachii)
undamaged. Proponents of low frequency PEMFT would argue that enhanced muscle blood flow
could only occur if the PEMFT device was applied to injured tissue. However, pilot data using two
men who were of similar characteristics to those used in the present study measured changes in
muscle blood flow and oxygenation of the elbow flexors in the non-dominant arm using NIRS
during the 30 minutes of e-cell™ treatment applied at 30 minutes, and 1 – 4 days after the same
eccentric exercise used in the present study, also showed no increase in muscle blood flow and
oxygenation.
Therefore, it was concluded that e-cell™ treatment induced a small increase in muscle
temperature but had no effect on muscle blood flow or oxygenation. Despite the lack of changes in
muscle blood flow and oxygenation, it does not necessarily mean that e-cell™ treatment can not
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enhance the healing of injured tissue, because there are other potential physiological mechanisms of
PEMFT, suggested in Figure 1, that were not been tested for in the present study.

5.2 Study 2
5.2.1 Exercise
To investigate the efficacy of interventions, arm-to-arm comparison models are often used
(Nosaka, et al., 2007; Nosaka, et al., 2004; Zainuddin, et al., 2006). The present study used an armto-arm comparison design in preference to a between-subjects design. The arm-to-arm comparison
model was thought to be advantageous, because only one group of participants were required thus
the total number of participants was reduced, and the within-subjects design allows for reduced
variability in response to exercise created by heterogeneous participants (Newton, Sacco, Chapman,
& Nosaka, 2013). Indeed, there were no significant differences in the dependent variables at preand immediately post-exercise when arm dominance, treatment and bout order were
counterbalanced.
The eccentric exercise protocol used in this study was effective for inducing significant losses
in strength and ROM, increases in swelling, tenderness and plasma CK activity as well as moderate
increases in muscle soreness. The changes in the dependent variables after maximal eccentric
exercise of the elbow flexors such as the immediate losses in MVC torque (∼55% of pre-exercise
measures) were equivalent to those of the previous studies in which a similar exercise protocol was
used (Newton, et al., 2008; Nosaka, et al., 2007; Zainuddin, et al., 2006). Thus, the exercise
protocol induced sufficient muscle damage to validate the efficacy of e-cell™ treatment.

5.2.2 Reliability of Measurements
For the test-retest reliability of the dependent variables (Table 1), the ICC measures were in
the 0.81 – 1.0 range indicating good reliability (Landis & Koch, 1977). In addition, the CV values
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were less than 10% for all variables indicating good reliability that allows for the detection of a
possible treatment effect. No significant differences in pre-exercise measures were evident for any
dependent variables, and the exercise protocols were performed similarly between the e-cell™ and
sham treatment groups as indicated by the similar average peak torque (Figure 16) production and
overall work performed during exercise (Figure 17). Similarly, there were no significant differences
in any dependent variables immediately after exercise between e-cell™ and sham conditions. Thus,
the eccentric exercise appeared to induce similar magnitude of muscle damage to both arms.
Therefore, it is reasonable to assume that if there are any differences in the dependent variables
between e-cell™ and sham conditions occurring after 60 minutes post-exercise, the changes can be
attributed to the effects of the treatment, given the primary treatment was applied 30 minutes postexercise. Lastly, when comparing between the first and second bouts of exercise, there were no
significant differences in pre- and immediately post-exercise measures for any of the dependent
variables.

5.2.3 Gender Effect
In the present study, no gender differences were found for the changes in muscle damage
markers following maximal eccentric exercise of the elbow flexors except for PPT (Table 2), where
a significantly faster recovery was seen for men than women, but the magnitude of difference was
small. Similar findings have been reported in a previous study where females expressed
significantly higher sensitivity and lower thresholds to PPT compared to males (Chesterton, Barlas,
Foster, Baxter, & Wright, 2003). As suggested previously in the methods section of this thesis,
females with high levels of oestrogen can experience attenuated symptoms from muscle damaging
exercise (Kendall & Eston, 2002). The mechanism of this protective effect is not fully understood
but it is believed that elevated levels of oestrogen have antioxidant properties facilitating cell
membrane stability attenuating the magnitude of muscle damage (Carter, Dobridge, and Hackney,
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2001). In the present study, when comparing the effect of e-cell™ and sham treatments for each
gender group separately, essentially the results were the same as those based on both groups
combined. Consequently, the comparisons between the e-cell™ and sham treatments shown below
were made for all participants.
The lack of gender differences found in the present study is in accordance with previous
gender studies (Rinard, et al., 2000; Sayers & Clarkson, 2001), but these studies did not measure
PPT. Despite the lack of gender differences seen in the present study, there is conflicting evidence
in the literature with some studies reporting that gender differences exist for the changes in muscle
damage markers particularly with regards to losses in MVC torque and smaller increases in plasma
CK activity (Stupka et al., 2000). For example, Seawright et al. (2008) compared the muscle
damage markers between 58 women and 42 men after 50 maximal eccentric contractions of the
elbow flexors and reported that women showed greater relative MVC torque losses than men
immediately after exercise, but men had significantly higher peak CK activity than women. This
was contrary to our findings where we found no significant MVC torque losses between genders
immediately post-exercise and additionally, no gender differences in plasma CK activity.
Furthermore, despite the previous findings from Seawright et al. (2008), our results revealed that
females exhibited greater increases in plasma CK activity than men, although this was not
significantly different. A study by Carter, Dobridge, and Hackney (2001), found that females with
high levels of oestrogen had significantly smaller increases in plasma CK activity 72 hours
following a 30 minute downhill running eccentric exercise protocol compared to low estrogen level
females. In the present study, females were deliberately tested during the mid-follicular phase of
their menstrual cycle (when oestrogen levels were low) to minimise any protective effect caused by
high levels of oestrogen. Thus, controlling of the menstrual cycle at the beginning of the exercise
bouts may have blunted any gender differences that may have otherwise been seen. Despite the
conflicting previous research, the results of the present study suggest that when the menstrual cycle
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is controlled for, gender had little effect on changes in the indirect markers of muscle damage after
the maximal eccentric exercise of the elbow flexors.

5.2.4 Acute Effect
The acute effect was based on the measures taken before and immediately after e-cell™ and
sham treatments. No significant changes in the dependent variables except MVC torque were found
before and immediately after either treatment performed 1-4 days after eccentric exercise (Figures
18 - 22). MVC torque decreased significantly around 8% immediately after both treatments (Figure
18). In the present study, the decreases seen in MVC torque were most likely related to factors
associated with a relaxation effect because the subjects were required to remain still and seated for
the entire 30 minute treatment duration, which may have led to a reduced efficiency of excitationcontraction coupling, decreased central motor drive and motor neuron excitability, or a combination
of all three (Gandevia, 2001).
It is unclear why no acute effect of e-cell™ treatment was seen, particularly as an overall
effect was evident. Given that PEMFT is reported to reduce pain and inflammation in
musculoskeletal injuries (Hedan & Pilla, 2008; Trock, et al., 1993), acute changes in muscle
soreness, tenderness and swelling after e-cell™ treatment may have been expected. It has been
previously suggested that PEMFT can enhance muscle blood flow (Markov, 2007), which can
increase venous drainage and reduce swelling. However, the present study was unable to detect any
significant change in blood flow from Study 1, and subsequently no acute effect on upper arm
circumference or other markers of muscle damage. Nevertheless, it might be that the beneficial
effects of the treatment could take effect sometime within the 24-hour period between treatment
applications. Therefore, it is possible that the effect of e-cell™ treatment could have been observed
in the hours after the 30 minutes of application in a similar manner to cold-water immersion where
the benefits of the cooling effect occur in the hours after the treatment has ceased (Pournot,
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Bieuzen, Duffield, Lepretre, Cozzolino & Hausswirth, 2011). However, the exact mechanism is
unknown and any future studies investigating the effects of e-cell™ treatment would be advised to
monitor the subsequent hours after the treatment application.

5.2.5 Effect of PEMFT on recovery from muscle damage
There were no acute effects of e-cell™ treatment on the changes in most of the dependent
variables but interestingly, there was a significantly faster rate of recovery after e-cell™ treatment
for all of the dependent variables except for extension soreness after maximal eccentric exercise
compared to sham treatment (Figures 23 - 30). The recovery of MVC torque is perhaps the most
important marker of muscle damage, since it affects exercise performance and activities of daily
living. To the best of my knowledge, no previous studies have found any enhanced recovery of
MVC torque after the use of a therapeutic electrotherapy treatment, although some of them reported
significant effects on other variables such as muscle soreness and plasma CK activity (Bakhtiary, et
al., 2007; Lau & Nosaka, 2011; Zainuddin, et al., 2005). The present study showed a significantly
faster rate of recovery (10.3 ± 5.0%) for MVC torque after e-cell™ compared to sham treatment at 7
days post-exercise, but MVC torque did not fully recover to baseline measures (Figure 23). Posthoc tests revealed significant differences were present on 2, 5 and 7 days post-exercise. Thus, it
appears the physiologically beneficial effects of e-cell™ treatment for MVC torque recovery were
not immediate and took time to develop. This is in accordance with the lack of acute response seen
for e-cell™ treatment reported previously in the present study for days 1 – 4 post-exercise (Figure
18). The present study was the first to show a more rapid recovery of MVC torque of the elbow
flexors after eccentric exercise following the application of low frequency PEMFT. It is difficult to
compare the results of the present study with other electrotherapy studies treating muscle damage,
because there are differences in the type and magnitude of muscle damaged, and the mode, duration
and the applied time of the electrotherapies. It is unclear from the present study whether longer
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treatment duration would generate a similar or greater magnitude of MVC torque recovery. Further
studies are necessary to investigate whether modifications to treatment duration and parameters
would generate a more rapid MVC torque recovery.
In terms of muscle function, it should be noted that not only MVC torque but also the
recovery of ROM of the elbow joint was enhanced by e-cell™ treatment. There were significantly
smaller decreases in elbow joint ROM for e-cell™ treatment compared to sham treatment (Figure
24). Similarly, Spodaryk (2002) observed significantly smaller decreases in ROM on 2 days after
applying a low frequency PEMFT device for 20 minutes over 5 days after exhaustive eccentric
dumbbell exercise of the elbow flexors compared to sham and control groups. Even though e-cell™
treatment enhanced the rate of recovery of the elbow joint ROM, the magnitude of difference
between e-cell™ and sham treatment in the present study appears less significant than other
electrotherapies. Previous studies using microwave (Nosaka, et al., 2007) and vibration (Lau &
Nosaka, 2011) therapy also reported improved recovery in elbow joint ROM, but the magnitude of
effect in these studies appears to be greater than that observed in the present study. For example,
Nosaka et al. (2007) and Lau et al. (2011) found significant differences between their respective
electrotherapies and control condition after EIMD on days 1 - 4 and 3 - 7 respectively compared to
only day 1 seen in the present study. Thus, it appears that low frequency PEMFT may not greatly
enhance elbow joint ROM compared to other thermal and mechanical electrotherapies. It is unlikely
e-cell™ treatment had any influence on joint stiffness (EANG) given the relatively small muscle
temperature increase found in Study 1. Spodaryk (2002) proposed that PEMFT treatment retarded
the perception of pain allowing for greater extension in elbow joint ROM; although in the present
study, this did not appear possible since there was no difference in soreness measures between
treatment conditions on day 1 after exercise. All things considered, despite the statistically
significant differences found for elbow joint ROM in the present study between conditions, it
appears the effect of e-cell™ treatment was not as clinically significant as other electrotherapies.
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Swelling transpires within the muscle immediately after maximal eccentric exercise-induced
muscle damage of the elbow flexors and typically peaks around five days post-exercise (Nosaka &
Clarkson, 1996), which was confirmed in the present study. The amount of swelling induced postexercise in this study was similar to that of previous studies (Chen et al., 2012; Zainuddin et al.,
2006). In the present study there was significantly less swelling 60 minutes and 2 – 5 and 7 days
post-exercise after e-cell™ compared to sham treatment; and furthermore, significantly less (47.4 ±
8.4%) peak swelling was observed on day 5 after e-cell™ treatment compared to sham (Figure 25).
Interestingly, after the first 30 minute application of e-cell™ treatment there was significantly less
swelling (60 minutes post-exercise) compared to sham treatment, suggesting that low frequency
PEMFT may suppress oedema that occurs during the early stages of secondary damage, which has
been shown in a previous animal study (Lee, Maffulli, Li, & Chan, 1997). This is further supported
by studies that have shown PEMFT can reduce oedema in musculoskeletal injuries (Bentall, 1986;
Markov & Pilla, 1995). Therefore, based on the upper arm circumference results from the present
study, it appears that PEMFT can effectively reduce swelling of the upper arm.
Regarding DOMS, which is one of the most commonly used indirect markers of eccentric
exercise induced muscle damage (Cheung, et al., 2003), e-cell™ treatment induced a significant
reduction in palpation soreness (Figure 26) at 2, 4 and 7 days post-exercise and about a 10%
reduction in peak soreness (Figure 27) compared to sham treatment. There was also significantly
faster recovery of PPT values (Figure 28) after e-cell™ treatment with significantly less tenderness
(9 – 15%) seen everyday from 2 days post-exercise returning to baseline measures by day 4
compared to day 7 for sham condition. This was not surprising given that Spodaryk (2002) also
reported significantly less tenderness (∼20%) for days 3 - 5 post-exercise after applying low
frequency PEMFT and may lend credence helps to the potential increased inhibition of group III
and IV nerve fibres (Figure 1) which may have assisted to reduce the sensation of pain. In the
present study, even though e-cell™ treatment attenuated palpation soreness, the magnitude of effect
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may not be as significant as other therapeutic interventions. For example, Zainuddin et al. (2005)
employed 10 minutes of massage therapy 3 hours after 60 maximal eccentric contractions of the
elbow flexors that resulted in significant decreases (20 – 40%) in the severity of soreness measures
compared to control condition. Furthermore, Lau et al. (2011) applied 30 minutes of vibration
therapy 30 minutes and 1 - 4 days post-eccentric exercise of the elbow flexors and found significant
reductions (25 – 30%) in peak palpation soreness between days 2 – 5. In the present study, it should
be noted that while e-cell™ treatment attenuated palpation soreness, VAS measures from extension
soreness were not significantly different between conditions. It is unclear why e-cell™ treatment
would have an attenuating effect on palpation soreness and not extension soreness; but perhaps
there are different mechanisms of pain linked to palpation soreness compared to soreness associated
with movement that low frequency PEMFT devices may influence. Nevertheless, e-cell™ treatment
had a small but significant attenuation of palpation and peak soreness after EIMD but is perhaps not
as significant compared to other therapeutic interventions such as vibration therapy.
Another indirect marker of muscle damage is plasma or serum CK activity that typically
peaks 4 – 6 days after maximal eccentric exercise of the elbow flexors, which was confirmed in the
present study (Clarkson, Nosaka, & Braun, 1992). Plasma CK activity increased significantly in
both treatments after exercise; however, significantly less mean (Figure 29) and peak plasma CK
activity (Figure 30) was seen after e-cell™ compared to sham treatment. To the best of my
knowledge, this is the first study to show that PEMFT can attenuate increases in plasma CK
activity. It is difficult to compare the results from the present study with other electrotherapy studies
due to the differing treatment and exercise protocols. However, it appears the magnitude of e-cell™
treatment effect on plasma CK activity is greater than other electrotherapy studies. For example,
Lau et al. (2011) and Nosaka et al. (2004) found no significant difference between their respective
treatments (vibration and microwave diathermy respectively) and control condition on reducing
increases in plasma CK activity. In the present study the reduced plasma CK activity after e-cell™
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treatment could possibly be explained by smaller CK efflux from the damaged muscle (Figure 1)
but is unlikely to be caused by increased clearance of plasma CK from circulatory factors as no
changes in muscle blood flow were found from Study 1. However, there is no evidence to support
these speculations in the present study.
The results from the present study support the effectiveness of e-cell™ treatment in the
attenuation of symptoms associated with EIMD. Previously, PEMFT has been shown to be effective
in the recovery of muscle tenderness and losses in ROM following EIMD, but to the best of my
knowledge, this is the first study to demonstrate the effectiveness of PEMFT in the recovery of
muscle strength, soreness, swelling and plasma CK activity. Thus, the findings from this study, in
regards to the recovery of muscle damage markers following EIMD, are important for athletes to
assist in their recovery after training and competition as well as the general population.
It is difficult to determine how e-cell™ treatment enhanced the recovery of muscle damage
but some speculation is possible. It is well known that secondary muscle damage (inflammatory
processes that follow the primary damage of eccentric exercise) associated with an inflammatory
response can contribute to swelling and prolonged strength losses (Clarkson & Hubal, 2002).
Additionally, inflammation in skeletal muscle is characterised by the infiltration of neutrophils and
macrophages that are associated with muscle injury and repair (Hernandez et al., 1987). Neutrophils
are also known to proliferate around the site of injury in the early stages of inflammation. With this
in mind, it has been shown that adenosine (thought to be an endogenous anti-inflammatory agent
that activates A2a receptors found on neutrophils) can bind to neutophil receptors and decrease
inflammatory processes (Huang, Apasov, Koshiba, & Sitkovsky, 1997). Varani et al. (2002) showed
that low frequency PEMFT exposure can significantly enhance the function and expression of
adenosine A2a receptor activity in human neutrophils in vitro, which could play an in important role
in modulating inflammatory processes that could benefit therapeutic healing (Cronstein,
Montesinos, & Weissmann, 1999). Therefore, it could be speculated that e-cell™ treatment helped
to attenuate the early inflammatory response to EIMD and facilitate the recovery of strength and
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swelling. Electromagnetic fields are also believed to affect cell membrane function by influencing
the rate of ion binding and transport to receptor sites and influence tissue repair (Bersani et al.,
1997; Markov, 2007). The reduced efflux of plasma CK into the blood stream reported in the
present study may support this argument (Figure 1). As previously mentioned, PEMFT treatment
has been shown to reduce acute/chronic inflammation occurring from musculoskeletal injuries. All
things considered, it is believed the primary function of low frequency PEMFT treatment is to
suppress the extravascular oedema during the early stages of an inflammatory response.
It is not fully understood how the e-cell™ treatment attenuated palpation soreness and PPT.
However, it could be speculated that the electromagnetic fields from low frequency PEMFT devices
may influence DOMS and muscle tenderness by impeding the sensory input from the nociceptors to
the afferent fibres (type Aδ and C) reducing the perception of pain (Figure 1) (Robertson et al.,
2006). As previously reported within this discussion, e-cell™ treatment also reduced swelling
around the elbow flexors, which may have also contributed to the smaller increases in the sensitivity
of the nociceptors to palpation soreness, as swelling is believed to contribute to hyperalgesia of the
nociceptors (Sluka, Jordan, & Westlund, 1994). However, based upon the comparison between the
first and second bouts of eccentric exercise for the e-cell™ treatment effect (Figure 39), it appears
that PEMFT had the greatest attenuating effect on markers of inflammation since the greatest
magnitude of protection conferred by e-cell™ treatment was evident on swelling (Figures 39 & 40).
Further studies are necessary examine the underlying mechanisms of PEMFT treatment.

5.2.6 Repeated Bout Effect
In the present study, when the second bout of exercise was performed 4 weeks after the first
bout (ignoring the treatment effect between e-cell™ and sham conditions) there were significantly
smaller changes in all of the dependent variables on the contralateral arm compared with the first
bout, suggesting an arm-to-arm cross transfer effect (Figure 31 - 38). At least three studies have
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reported the existence of the contralateral repeated bout effect for the elbow flexors (Howatson &
Van Someren, 2007; Newton, Sacco, Chapman, & Nosaka, 2013; Starbuck & Eston, 2012).
However, it should be noted that the first and second bouts were not the same conditions such that
one of the bouts was for e-cell™ condition and the other was for sham condition. In contrast, the
previous studies (Howatson & Van Someren, 2007; Newton et al., 2013; Starbuck & Eston, 2012)
investigated the contralateral repeated bout effect without any additional effect.
For the changes in MVC torque in the present study, a significantly faster rate of recovery for
strength was seen after bout 2 compared to bout 1, with significant differences observed on days 2 –
5 and 7 days post-exercise with ∼12% greater strength recovery observed on day 2 after the second
bout compared to the first, and this trend continued to day 7 (Figure 31). Previous studies have also
reported significantly faster recovery of strength on the contralateral arm after the second bout of
exercise compared to the first (Howatson & Van Someren, 2007; Newton et al., 2013; Starbuck &
Eston, 2012). Our findings were similar to observations reported by Newton et al. (2013), in which
two bouts were separated by 4 weeks, the same as that of the present study. However, the
magnitude of strength recovery in the present study does not appear to be as significant as that
found by Howatson and Van Someren (2007) and Starbuck and Eston (2012) whose subjects
performed exercise bouts with only 2 weeks separation. It may be that the contralateral repeated
bout effect is attenuated with increasing the interval between bouts as shown in the ipsilateral
repeated bout effect (Nosaka, Sakamoto, Newton, & Sacco, 2001).
A significantly faster rate of recovery for ROM was also observed for days 1 – 5 following
bout 2 compared to bout 1 (Figure 32). Interestingly, previous studies exhibiting the contralateral
repeated bout effect found no significant difference between bouts 1 and 2 for the recovery of ROM
following EIMD (Howatson & Van Someren, 2007; Newton et al., 2013; Starbuck & Eston, 2012).
It is not clear why significant differences in ROM were evident in the present study and not in the
previous contralateral repeated bout studies. It must be noted that Howatson and Van Someren
(2007) and Starbuck and Eston (2012) only measured elbow joint ROM for three time points (pre-,
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48 and 96 hours and pre-, 24 and 48 hours respectively) instead of nine time points in the Newton et
al. (2013) and present study which may have influenced the statistical significance of their findings.
Besides the enhanced muscle function, there were also significantly smaller increases in upper
arm circumference after bout 2 compared to bout 1 (Figure 33). Newton et al. (2013) also reported
significantly less swelling after bout 2 compared to bout 1, but the magnitude of effect after the
second bout in the present study appears to be greater given that significant differences were found
for every time point after 60 minutes post-exercise compared to day 7 only in the Newton et al.
(2013) study. Interestingly, Howatson and Van Someren (2007) found no significant contralateral
repeated bout effect for upper arm circumference; although a direct comparison should not be made
since the interval between bouts differed to the present study. Starbuck and Eston (2012) did not
measure upper arm circumference.
Compared to bout 1, palpation (Figure 34), peak (Figure 35) and extension soreness were all
significantly attenuated in bout 2. Significant differences were seen from days 2 – 5 post-exercise
for palpation soreness, while peak soreness was ∼35% lower after the second bout compared to the
first. Similarly, the recovery of muscle tenderness was significantly faster after bout 2 compared to
bout 1, with PPT values returning to baseline after 5 days post-exercise in the second bout
compared to day 7 in the first bout (Figure 36). The three previous contralateral repeated bout effect
studies did not include PPT measures. However, with regards to DOMS, Howatson and Van
Someren (2007) and Starbuck and Eston (2012) also found significantly less muscle soreness
develop in the elbow flexors after bout 2 compared to bout 1 although a direct comparison should
be treated with caution as the previously mentioned studies assessed extension soreness only. In
contrast, Newton et al. (2013) found no significant difference in extension soreness of the elbow
flexors between the first and second bouts.
The second bout of exercise also attenuated increases in plasma CK activity compared to the
first with significant differences seen from day 3 onwards (Figure 37). In addition, significantly less
(∼45%) peak plasma CK activity was evident following bout 2 compared to bout 1 (Figure 38). The
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blunted plasma CK activity following the second bout in the present study is in accordance with
previous studies (Howatson & Van Someren, 2007; Newton et al., 2013; Starbuck & Eston, 2012).
These findings from the present study provide further evidence for the existence of the
contralateral repeated bout effect. These results follow a similar trend to that found in previous
research and suggest the adaptations to a contralateral repeated bout of exercise are primarily
determined by centrally mediated neural mechanisms as there is no direct stimulus for cellular or
mechanical adaptations to develop in the unexercised limb (Howatson & Van Someren, 2007;
Newton et al., 2013; Starbuck & Eston, 2012). It should be noted that the contralateral repeated
effect found in the present study could be a combination of the contralateral repeated bout effect
and the treatment effect.
The crossover design was chosen in this study, as it requires a smaller number of subjects and
allows for reduced variability in molecular responses to exercise created by heterogeneous subjects
(Chen, Hubal, Hoffman, Thompson, & Clarkson, 2003). The present study showed that the
magnitude of the e-cell™ treatment effect was greater for the first bout (the subjects who had either
the e-cell™ or sham treatment for the first bout only were compared) than the second bout (the
subjects who had either the e-cell™ or sham treatment for the second bout only were compared)
using a smaller number (n=8) of subjects (Figure 40). Interestingly, the magnitude of the e-cell™
treatment effect was smaller for the second bout than the first bout. This suggests that the
contralateral repeated bout effect could have affected the results such that the smaller effect found
in the second bout was the combination of the treatment effect and the contralateral repeated bout
effect. Importantly, the magnitude of the treatment effect found for the first bout was more similar
to the results of the overall magnitude of treatment effect (Figure 39 & 40). Therefore, it appears
that the crossover design is acceptable for validating the intervention. However, it should be
cognisant that the contralateral repeated bout effect could affect the results when the arm-to-arm
comparison model is used. Future studies assessing the effects of prophylactic or therapeutic
interventions on muscle damage may look to extend the washout period between exercise bouts if
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an arm-to-arm comparison model is used, or separate subjects into either control or intervention
group so that a prior bout of exercise does not influence the outcome measures.

5.2.7 Comparison between the Treatment Effect and the Repeated Bout Effect
As discussed above, it appears that the magnitude of the contralateral repeated bout effect was
greater than the effect of e-cell™ treatment (Figure 39). For example, on day 5 e-cell™ treatment
only improved the rate of recovery for MVC torque, ROM, peak soreness and PPT by
approximately 9%, 4%, 11% and 13%, respectively (Figure 40). On the other hand, the contralateral
repeated bout effect improved the rate of recovery for the same muscle damage markers on day 5 by
almost 18%, 8%, 35% and 20% respectively (Figure 39). It is not realistic that one arm is damaged
to protect the other arm from muscle damage, but several studies have shown that non-damaging
exercise consisting of either low-intensity eccentric contractions (Chen et al., 2011) or maximal
contractions at a long muscle length (Chen, Nosaka, Pearce, & Chen, 2012) confers a protective
effect against muscle damage induced by maximal eccentric contraction. These studies have shown
that the magnitude of muscle damage is greatly reduced when non-damaging exercise was
performed previously (Chen et al., 2011, Chen et al., 2012). Furthermore, it appears that the
protective effect induced by non-damaging or pre-conditioning exercise may be greater than was
shown by the e-cell™ treatment found in the present study. Therefore, pre-conditioning the muscle
with a prior bout of exercise could be more effective at attenuating symptoms associated with
EIMD compared to e-cell™ treatment. Since there are no costs for the pre-conditioning exercise, it
might be that e-cell™ treatment may not be the best choice for the attenuation of muscle damage
induced by eccentric exercise.
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5.3 Conclusion
In summary, the present study showed recovery of muscle damage markers were faster with
e-cell™ treatment compared with sham treatment. However, it is evident that the contralateral
repeated bout effect may have been a confounding factor that provided a protective effect in the
second bout of exercise for both conditions. It has been reported that pre-conditioning the muscle
using maximal isometric contractions or sub-maximal eccentric exercise, which are non-damaging,
can have a strong protective effect against muscle damage. However, it is not known whether the
magnitude of the protective effect conferred by pre-conditioning exercise is stronger than the
magnitude of the e-cell™ treatment effect. Therefore, if the e-cell™ treatment effect is weaker than
the effect of pre-conditioning exercise, then pre-conditioning exercise should be recommended in
preference to e-cell™ treatment because it can be administered with minimal cost and the equipment
can be easier to access. However, if no pre-conditioning exercise was performed, and muscle
damage was induced, e-cell™ treatment seems to be a good option to enhance recovery from
eccentric exercise-induced muscle damage. There are many causes of muscle damage, and eccentric
exercise-induced muscle damage is only one of them. Further studies are necessary to investigate
the effect of e-cell™ treatment on other soft tissue injuries, since it is anecdotally believed to
enhance recovery from more severe injuries such as a skeletal muscle tears.
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APPENDIX B: STUDY 1 - INFORMATION LETTER

Information Letter to Participants
Title of the Project: Effects of Pulsed Electromagnetic Field Therapy on Symptoms
Associated with Eccentric Exercise-Induced Muscle Damage.
Study 1
Investigator: Harry Banyard (MSc. Candidate)
Principle Supervisor: Professor Ken Nosaka
Co-Supervisor: Associate Professor Michael Newton
School of Exercise, Biomedical and Health Sciences
Edith Cowan University
270 Joondalup Drive, Joondalup WA 6027
Thank you for expressing an interest in the study. The purpose of this information letter is to
provide you with an overview of the study in which you may participate in as a subject.
Purpose of the study
The purpose of this study is to investigate whether 30 minutes of e-cell™ treatment increases
muscle temperature, blood flow and oxygenation when it is applied to the elbow flexor muscles (in
particular the biceps brachii).
Background
Pulsed electromagnetic field therapy (PEMFT) is a therapeutic treatment that produces magnetic
waves to penetrate deeply through tissues without contact, where the magnetic pulses are believed
to enhance cellular repair. Previous research has shown PEMFT to reduce pain, swelling and
inflammation relating to musculoskeletal injuries, and enhance the tissue regeneration process. For
this to occur it seems likely that PEMFT can increase muscle oxygenation and blood flow, but no
previous study has investigated the effects of PEMFT on muscle temperature or these other factors.
A portable PEMFT device called e-cell™ produces low frequency, low power electromagnetic
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fields, and has been anecdotally claimed to enhance the healing processes of soft tissue injuries.
Therefore this will be the first study to investigate whether PEMFT can enhance muscle
temperature, muscle oxygenation and blood flow simultaneously.
Methods
As a participant in this study you are required to attend 2 testing sessions (24 hours apart) for a
duration of approximately 45 mins/session at Edith Cowan University, Joondalup Campus,
commencing in the exercise physiology lab, building 19, room 19.150. A company (Global Energy
Medicine) has provided two e-cell devices that generate electromagnetic pulses at different
frequencies. You and the investigator are blinded to the devices (only informed as Device A and
Device B). The testing session will involve a series of assessments designed to test the effectiveness
of the e-cell™ device to increase muscle temperature, muscle oxygenation and blood flow.
Subjects
As a volunteer, you must be aged between 18 to 45 years for this study. You must complete an
informed written consent form and a medical questionnaire before participating in the study.
Procedure
During the testing session one arm will receive e-cell™ treatment at a low frequency and for the
other testing session the other arm will receive treatment at a different frequency. You will be asked
to lay supine on a massage table and required to keep your treatment arm as still as possible until
the treatment period concludes to minimise changes in blood flow due to movements. The device
(similar in shape and size to a computer mouse and weighing approximately 100g) will be placed
longitudinally along the lateral aspect of your biceps brachii (outer upper arm) and held in place by
a Velcro strap. The treatment will be applied for 30 min. The device will be switched on, where
green and red lights will flash to indicate it is operating and then turned off after 30 min of
treatment indicated by the sound of a double beep.
Muscle Temperature
A thermometer will measure your biceps brachii muscle temperature with a needle thermistor probe
that will be inserted to a depth of 20 mm at a 45 angle into the belly of your biceps brachii. Three
measurements will be taken 5 min before, immediately after, and 10 min after treatment.

85

Muscle Oxygenation and Blood flow
Near infrared spectroscopy (NIRS) is a non-invasive technique that will be employed to monitor
muscle oxygenation and blood flow in the biceps brachii muscles. The probe unit of the NIRS
system will be firmly attached to the skin at the mid-belly of your biceps brachii with double-sided
adhesive tape to ensure no sliding of the probe on the skin. The NIRS probe in relation to the
treatment device will be aligned adjacently. The NIRS system will record your muscle oxygenation
and blood flow levels commencing 5 min prior (resting value) to “e-cell” treatment and continue
until 10 min after the “e-cell” treatment concludes.
Potential Risks
In very rare instances, the muscle temperature procedure can lead to bleeding or bruising that might
cause pain and make using the muscle difficult for a few days. To avoid the chances of infection,
the investigator will wear gloves and use a sterilized needle. The insertion site will also be cleaned
and prepared with alcohol wipes.
Potential Benefits
You will have the chance to observe how current research techniques are performed and you may
also gain an insight and understanding about the test involved.
Privacy and Confidentiality
All information collected during this research remains confidential and will not be used for any
other purpose other than this study. All data collected will be stored securely on ECU premises and
kept for 5 years after the completion of the project and then destroyed.
Participation in the Study
Participation in this research is entirely voluntary and you may refuse to participate or withdraw at
anytime without adverse consequences.
If you have any questions about the research project or require further information you may contact
the following:
Student Researcher: Henry Banyard
Telephone: (08) 6 304 5156
Email: h.banyard@ecu.edu.au
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Principal Supervisor: Prof. Ken Nosaka
Telephone: (08) 6 304 5655
Email: k.nosaka@ecu.edu.au
Co-Supervisor: Associate Prof. Michael Newton
Telephone: (08) 6 304 4132
Email: m.newton@ecu.edu.au
If you have any ethical concerns with regards to your participation in this study you may contact:
Research Ethics Officer: Kim Gifkins
Phone: (08) 9304 2170
Address: Human Research Ethics Committee, Edith Cowan University, 100 Joondalup Drive,
Joondalup WA, 6027
Email: research.ethics@ecu.edu.au
Thank you for your time,
Yours sincerely,
Harry Banyard
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APPENDIX C: STUDY 1 - INFORMED CONSENT FORM

Subject Informed Consent Form
Study 1
I ___________________________, consent to participating in the research project entitled:
“Effects of Pulsed Electromagnetic Field Therapy on Symptoms Associated with
Eccentric Exercise-Induced Muscle Damage”.
Statement indicating consent to participate
I confirm the following:
•

I have been provided with the “Information Letter” explaining the research study

•

I have read and understood the information provided and the procedures of the study

•

I have been given an opportunity to ask questions and I have had any questions answered to
my satisfaction

•

I am aware that if I have any additional questions, I can contact the research team

•

I understand that participation in the research project will involve:
o Two testing sessions where one arm will receive e-cell™ treatment and the other arm
will receive sham treatment
o Measurements of muscle temperature, muscle oxygenation and muscle blood flow
o Possible muscle soreness after muscle temperature measurements

•

I understand that my information provided will be kept confidential, and that my identity
will not be disclosed without consent

•

I understand that the information provided will only be used for the purposes of this research
project, and I understand how the information is to be used

•

I understand that I am free to withdraw from further participation at any time, without
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explanation or penalty
•

I freely agree to participate in the project

Participant Name

Date (DD/MM/YYYY) _______________

Researchers Name

Date (DD/MM/YYYY)
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APPENDIX D: STUDY 1 - MEDICAL QUESTIONNAIRE

Medical Questionnaire
Project Title: Effects of pulsed electromagnetic field therapy on symptoms associated with
eccentric exercise induced muscle damage.
The following questionnaire is designed to establish a background of your medical history, and
identify any injury and/or illness that may influence your testing and performance. Please answer all
questions as accurately as possible, and if you are unsure about any aspect of this form, please ask
for clarification. All information provided is strictly confidential.
Personal Details
Name: _____________________________________
Date of Birth (DD/MM/YYYY): __________________ Gender: Male / Female
PART A YES / NO DETAILS
1. Are you a male over 45 years, or female over 55 years, who has had a hysterectomy or are
postmenopausal?
Y / N _________________
2. Are you a regular smoker, or have you quit in the last 6 months? Y / N _______________
3. Did a close family member have heart disease or surgery, or stroke before the age of 60 years?
Y / N _________________
4. Do you have, or have you ever been told you have blood pressure above 140/90 mmHg, or do
you currently take blood pressure medication?
Y / N _________________
5. Do you have, or have you ever been told you have a total cholesterol level above 5.2 mmol/L
(200 mg/dL)?
Y / N _________________
6. Is your BMI (weight/height) greater than 30?

Y / N _________________

PART B YES / NO DETAILS
1. Have you ever had a serious asthma attack during exercise?

Y / N _________________

2. Do you have asthma that requires medication?

Y / N _________________

3. Have you had an epileptic seizure in the last 5 years?

Y / N_________________
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4. Do you have any moderate or severe allergies?

Y / N _________________

5. Do you, or could you reasonably have an infectious disease? Y / N _________________
6. Do you, or could you reasonably have an infection or disease that might be aggravated by
exercise?
Y / N _________________
7. Are you, or could you reasonably be pregnant?

Y / N _________________

PART C YES / NO DETAILS
1. Are you currently taking any prescribed or non-prescribed medication?
Y / N __________________________________
2. Have you had, or do you currently have any of the following:•

Rheumatic Fever

Y / N _________________

•

Heart Abnormalities Y / N _________________

•

Diabetes

Y / N _________________

•

Epilepsy

Y / N _________________

•

Recurring back pain that will make exercise problematic, or where exercise may aggravate
pain?
Y / N _________________

•

Recurring neck pain that will make exercise problematic, or where exercise may aggravate
pain?
Y / N _________________

•

Neurological disorders that would make exercise problematic, or where exercise may
aggravate the condition?
Y / N _________________

•

Neuromuscular disorders that would make exercise problematic, or where exercise may
aggravate the condition?
Y / N _________________

•

Recurring muscle/joint injuries that would make exercise problematic, or where exercise
may aggravate the condition? Y / N _________________

•

A burning or cramping sensation in your legs when walking short distances?
Y / N _________________

•

Chest discomfort, unreasonable breathlessness, dizziness or fainting, or blackouts during
exercise?
Y / N _________________
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PART D YES / NO DETAILS
1. Have you had any influenza in the last week?

Y / N _________________

2. Do you currently have an injury that might affect, or be affected by exercise?
Y / N _________________
3. Have you had any minor or major injuries in the past 3 months? Y / N _______________ If so,
please list. Has this injury stopped you training or competing in one or more sessions? If so, how
many? _________________
4. Is there any other condition not previously mentioned that may affected your ability to
participate in this study?
Y / N _________________
Declaration – (to be signed in the presence of the researcher)
I acknowledge that the information provided in this form, is to the best of my knowledge, a true and
accurate indication of my current state of health.
Participant
Name: __________________________________ Date (DD/MM/YYYY): _______________
Signature: _________________________________________________________________
Researcher
Name: __________________________________ Date (DD/MM/YYYY): _______________
Signature: _________________________________________________________________
Practitioner (only if applicable)
I, Dr _______________________________ have read the medical questionnaire and the
information / consent form provided to my patient, Mr / Miss / Ms / Mrs _________________
__________________, and clear him / her medically for involvement in exercise testing.
Name: ________________________________Date(DD/MM/YYYY):____________
Signature:_____________________________________________________________
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APPENDIX E: STUDY 2 - INFORMATION LETTER

Information Letter to Participants
Title of the Project: Effects of Pulsed Electro Magnetic Field Therapy on Symptoms
Associated with Eccentric Exercise-Induced Muscle Damage.
Study 2
Investigator: Henry Banyard (MSc. Candidate)
Supervisor: Professor Ken Nosaka
School of Exercise, Biomedical and Health Sciences
Edith Cowan University
270 Joondalup Drive, Joondalup WA 6027
Thank you for expressing an interest in the study. The purpose of this information letter is to
provide you with an overview of the study in which you may participate in as a subject.
Purpose of the study
We are interested in investigating the potential effect of e-cell™ treatment in reducing changes of
muscle damage markers such as maximal voluntary contraction (MVC) strength, upper arm
circumference, range of motion (ROM), muscle soreness, and plasma creatine kinase (CK) activity
following eccentric exercise of the elbow flexors.
Background
Pulsed electro magnetic field therapy (PEMFT) is a therapeutic treatment that produces magnetic
waves to penetrate deeply through tissues without contact, where the magnetic pulses are believed
to enhance cellular repair. Previous research has shown PEMFT to reduce pain, swelling and
inflammation relating to musculoskeletal injuries, and enhance the tissue regeneration process. A
portable PEMFT device called e-cell™ produces low frequency, low power electromagnetic fields,
and has been anecdotally claimed to enhance the healing processes of muscle injuries. However, no
93

experimental studies have yet examined the effects of e-cell™ treatment on markers of muscle
damage induced by maximal elbow extension (eccentric) exercise. Therefore this will be the first
study to investigate whether 30 minutes of e-cell™ treatment performed 30 minutes, 1, 2, 3 and 4
days after eccentric exercise of the elbow flexors will reduce the associated symptoms and markers
of eccentric exercise-induced muscle damage.
Subjects
As a volunteer, you must be aged between 18 to 45 years for this study. You must complete an
informed written consent form and a medical questionnaire before participating in the study.
Female subjects will also be asked to complete a menstrual history questionnaire. You are also
requested not to perform unaccustomed exercise during the experimental period.
Participants are required to attend 16 sessions consisting of a familiarisation session (45 mins), a
reliability testing session (30 mins), 2 exercise sessions (180 mins/session) and 12 testing sessions
(90 mins/session) at Edith Cowan University, Joondalup Campus, commencing in the exercise
physiology lab, building 19, room 19.150.
Familiarisation session:
You will attend a familiarisation session at least one week before you participate in the study. Your
height and weight measurements will be recorded and you will complete a medical questionnaire to
ensure you do not present contraindications to participate in the study. You will perform 2 maximal
static (isometric) contractions at 90˚ and 2 maximal elbow flexion (concentric) contractions at a
velocity of 30˚·s− and 210˚·s− during this session. No elbow extension (eccentric) contractions
will be performed to minimise any muscle damage to the elbow flexors. However you will be
shown and briefed on the eccentric exercise protocol. Measurements such as range of motion, arm
circumference, muscle soreness and pressure pain threshold and plasma CK activity will also be
recorded.

Exercise Day
A company will provide two identical e-cell™ devices; one being the actual e-cell™ and the other
will not generate electromagnetic pulses (sham). Subjects will perform a bout of maximal eccentric
exercise of the elbow flexors of each arm 4 weeks apart. Female subjects will perform the exercise
after the luteal phase (lowest oestrogen levels) of their menstrual cycle, since oestrogen may have
an apparent protective effect on skeletal muscle and may therefore reduce the markers of eccentric
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exercise-induced muscle damage (Kendall & Eston, 2002). One arm will receive e-cell™ treatment
and the other arm will receive sham treatments on five occasions such as 30 minutes after the
exercise, and 1, 2, 3 and 4 days following the exercise. The treatment duration for each time point
will be 30 minutes, which is normally used in the e-cell™ treatment. To establish intra-rater
reliability for all dependant variables, two baseline measures will be taken at 3 days prior to and
immediately before the first eccentric exercise bout. Therefore the experiment period will include
one block of 8 days of testing (3 days before exercise, before and after exercise, 1, 2, 3, 4, 5, and 7
days post exercise) and one block of 7 days of testing (before and after exercise, 1, 2, 3, 4, 5, and 7
days post exercise). In the testing, isokinetic and isometric strength, range of motion, arm
circumference, muscle soreness and pressure pain threshold, and blood samples to assess plasma
CK activity will be taken.
The exercise session consists of 10 sets of 6 maximum voluntary eccentric contractions of the
elbow flexors against the lever arm of the isokinetic dynamometer moving at a constant velocity of
30˚·s−. You will be positioned on a seated preacher arm curl bench with a supinated forearm
position. The elbow joint will be forcibly extended from a flexed position (90˚) to a fully extended
position (180˚) in 3 seconds. Subjects will be verbally encouraged to generate a maximal isometric
force at the starting position and to maximally resist against the elbow extending action throughout
the full range of motion. After each eccentric action, the isokinetic dynamometer will return the arm
to the flexed position while you are asked to relax the arm at a constant velocity of 9˚·s−, creating a
10 second passive recovery between contractions. The rest period between sets will be 90 seconds.
A company (Global Energy Medicine) has provided two e-cell devices that generate
electromagnetic pulses at different frequencies. You and the investigator are blinded to the devices
(you are only informed of Device A and Device B).

Recovery Day
The recovery session days will involve a series of assessments that will be performed before and
immediately after e-cell™ treatment. During the testing session one arm will receive e-cell™
treatment at a particular frequency and for the other testing session the opposite arm will receive ecell™ treatment at a different frequency. You will be asked to lay supine on a massage table and
required to keep your treatment arm as still as possible until the treatment period concludes to
minimise changes in blood flow due to movements. The device (similar in shape and size to a
computer mouse and weighing approximately 100g) will be placed on the outside of your biceps
brachii muscle (longitudinally along the lateral aspect of your biceps brachii) and held in place by a
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Velcro strap. The treatment will be applied for 30 min. The device will be switched on, where green
and red lights will flash to indicate it is operating and then turned off.
Measurements
The following measurements will be taken from the exercise arm.
1. Maximal Static (Isometric) Strength: You will be asked to perform two 3-s maximal
isometric contractions at an elbow joint angle of 90˚, 120˚ and 150˚ (where 180˚ represents a
fully extended elbow joint angle) on the dynamometer in this order with 30 seconds rest
between contractions at the same joint angle and 60 seconds rest between contractions at
different joint angles.
2. Range of Motion: A plastic goniometer will be used to examine the range of motion (ROM)
of the elbow joint. Three types of joint angles will be measured; relaxed elbow joint angle
(arm relaxed by side), extended elbow joint angle (maximal arm extension without moving
the elbow) and flexed elbow joint angle (maximal arm flexion without moving elbow).
ROM measurement is calculated by subtracting flexed elbow joint angle from extended
elbow joint angle.
3. Upper Arm Circumference: A constant tension tape will be used to measure
circumference of the exercise limb while the arm is hanging relaxed by your side (palms
facing the thigh). The measurements will be taken from 3 upper arm sites and 1 forearm site
marked by a semi-permanent ink marker.
4. Muscle Soreness: The level of muscle soreness will be assessed using a 100 mm visual
analogue scale (VAS). On the scale, 0 mm indicates no pain and 100 mm represents extreme
pain. You will be asked to mark your level of perceived soreness on the VAS while the
corresponding joint is flexed and extended by the investigator. Palpation will also be applied
using the index and middle fingers slowly in a circular motion 5 times on four sites of the
upper arm including the mid-belly of the biceps brachii, 3 cm above and below the midbelly and the brachialis.
5. Pressure Pain Threshold (PPT): A device (electronic algometer) will be used to measure
pain in the exercised arm. Force will be gradually applied until you report the first feeling of
noticeable pain.
6. Plasma CK activity: A small amount of blood (30 µl) will be collected from your finger
and the blood will be analysed for plasma CK levels.
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Potential Risks
You may experience some degree of muscle soreness and decreases in muscle strength and ROM
for some days after exercise which may affect daily activities, therefore care must be taken. You
may also experience swelling of the upper arm and forearm. These are typical symptoms of
unaccustomed eccentric exercise induced muscle damage and will disappear in a week or so. If
symptoms exist for longer than a week you should inform the investigator who will provide you
with a letter explaining the study you participated in which can be presented to a doctor.
Potential Benefits
The potential benefits include the chance to observe how research is performed and gaining an
insight and understanding about the test involved.
Privacy and Confidentiality
All information collected during this research remains confidential and will not be used for any
other purpose other than this study. All data collected will be stored securely on ECU premises and
kept for 5 years after the completion of the project and then destroyed.
Participation in the Study
Participation in this research is entirely voluntary and you may refuse to participate or withdraw at
anytime without adverse consequences.
If you have any questions about the research project or require further information you may contact
the following:
Student Researcher: Harry Banyard
Telephone: (08) 6 304 5156
Email: h.banyard@ecu.edu.au
Principal Supervisor: Prof. Ken Nosaka
Telephone: (08) 6 304 5655
Email: k.nosaka@ecu.edu.au
Co-Supervisor: Associate Prof. Michael Newton
Telephone: (08) 6 304 4132
Email: m.newton@ecu.edu.au
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If you have any ethical concerns with regards to your participation in this study you may contact:
Research Ethics Officer: Kim Gifkins
Phone: (08) 9304 2170
Address: Human Research Ethics Committee, Edith Cowan University, 100 Joondalup Drive,
Joondalup WA, 6027
Email: research.ethics@ecu.edu.au
Thank you for your time,
Yours sincerely,
Harry Banyard
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APPENDIX F: STUDY 2 - INFORMED CONSENT FORM

Subject Informed Consent Form
Study 2
I ___________________________, consent to participating in the research project entitled:
“Effects of Pulsed Electro Magnetic Field Therapy on Symptoms Associated
with Eccentric Exercise-Induced Muscle Damage”.
Statement indicating consent to participate
I confirm the following:
•

I have been provided with the “Information Letter” explaining the research study

•

I have read and understood the information provided and the procedures of the study

•

I have been given an opportunity to ask questions and I have had any questions answered to
my satisfaction

•

I am aware that if I have any additional questions, I can contact the research team

•

I understand that I may experience severe muscle pain in the days after exercise

•

I am aware that my muscles will be weak for a week or two, or more than a month in rare
instances, which may affect the performance of daily activities

•

I am aware that my muscles may be swollen for several days after exercise

•

I understand that my information provided will be kept confidential, and that my identity
will not be disclosed without consent

•

I understand that the information provided will only be used for the purposes of this research
project, and I understand how the information is to be used

•

I understand that I am free to withdraw from further participation at any time, without
explanation or penalty
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•

I freely agree to participate in the project

Participant Name

Date (DD/MM/YYYY)

y

Researchers Name

Date (DD/MM/YYYY)

y

Signatures (Participant) _____________________ (Researcher) ____________________
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APPENDIX G: STUDY 2 - MEDICAL QUESTIONNAIRE

Medical Questionnaire
The following questionnaire is designed to establish a background of your medical history, and
identify any injury and/or illness that may influence your testing and performance. Please answer all
questions as accurately as possible, and if you are unsure about any aspect of this form, please ask
for clarification. All information provided is strictly confidential.
Personal Details

Name:______________________________________________

Date of Birth (DD/MM/YYYY):__________________

PART A

Yes / No

1. Are you a male or female over the age Y

Gender: Female/ Male

DETAILS

N

_____________________

Y

N

_____________________

Y

N

_____________________

of 45 years?

2. Are you a regular smoker or have you
quit in the last 6 months?

3. Did a close family member have heart
disease or surgery, or stroke before
the age of 60 years?
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4. Do you have, or have you ever been

Y

N

_____________________

Y

N

_____________________

Y

N

_____________________

Y

N

_____________________

Y

N

_____________________

Y

N

_____________________

4. Do you have any moderate or severe

Y

N

_____________________ allergies?

5. Do you, or could you reasonably, have

Y

N

_____________________

told you have blood pressure above
140/90 mmHg, or do you current take
blood pressure medication?

5. Do you have, or have you ever been
told you have, a total cholesterol level
above 5.2 mmol/L (200 mg/dL)?

6. Is your BMI (weight/height2) greater
than 30 kg/m2?

PART B

1. Have you ever had a serious asthma
attack during exercise?

2. Do you have asthma that requires
medication?
3. Have you had an epileptic seizure in
the last 5 years?

an infectious disease?
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6. Do you, or could you reasonably, have

Y

N

_____________________

Y

N

_____________________

Y

N

_____________________

an infection or disease that might be
aggravated by exercise?

7. Are you currently taking contraceptive
tablets?

8. Are you, or could you reasonably be
pregnant?

PART C

1. Are you currently taking any prescribed or non-prescribed medications?

Y

N

_____________________

2. Have you had, or do you currently have, any of the following?
DETAILS

•

Rheumatic fever

Y

N

_____________________

•

Heart abnormalities

Y

N

_____________________

•

Diabetes

Y

N

_____________________

•

Epilepsy

Y

N

_____________________
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•

Recurring back pain that would make

Y

N

_____________________

Y

N

_____________________

exercise problematic, or where exercise
may aggravate the pain

•

Recurring neck pain that would make
exercise problematic, or where exercise
may aggravate the pain

•

Any neurological disorders that would Y N

_____________________

make exercise problematic, or where
exercise may aggravate the condition

•

Any neuromuscular disorders that would Y

N

_____________________

Y

N

_____________________

A burning or cramping sensation in your Y

N

_____________________

N

_____________________

make exercise problematic, or where
exercise may aggravate the condition

•

Recurring muscle or joint injuries that
would make exercise problematic, or
where exercise may aggravate the
condition

•

legs when walking short distances

•

Chest discomfort, unreasonable

Y
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breathlessness, dizziness or fainting,
or blackouts during exercise

PART D

Have you had flu in the last week?

Y

N

_____________________

Do you currently have an injury that might Y

N

_____________________

affect, or be affected by, exercise?

*Is there any other condition not previously mentioned that may affect your ability to participate in
this study?

Y

N

_________________________________________________________

PART E (Female Subject)
Oestrogen may have a protective effect on muscle damage and could potentially reduce the markers
of eccentric exercise-induced muscle damage. Therefore the purpose of the following questions is
to determine the most suitable testing period for female subjects.
•

Are you currently taking birth control pills / estrogen pills?

•

If yes, what type? ________________________

•

Date of your last two menstrual cycles?

Y

N_____________
_____________________

_____________________
Declaration – (to be signed in the presence of the researcher)
I acknowledge that the information provided in this form, is to the best of my knowledge, a true and
accurate indication of my current state of health.
Participant
Name: __________________________________ Date (DD/MM/YYYY): ______________
Signature: _________________________________________________________________
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Researcher
Name: __________________________________ Date (DD/MM/YYYY): ______________
Signature: _________________________________________________________________
Practitioner (only if applicable)
I, Dr _______________________________ have read the medical questionnaire and the
information / consent form provided to my patient, Mr / Miss / Ms / Mrs _________________
__________________, and clear him / her medically for involvement in exercise testing.
Name: ________________________________Date(DD/MM/YYYY):____________
Signature:_______________________________________________________________
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